Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 1of 105Clinical Study Protocol 
Study Intervention PT010
Study Code D5985C00003
Version 2.0
Date 14 December 2023
A Randomized, Double -Blind, 12 -Week (with an Extension to 52 Weeks in a 
subset of Participants), Multi-Center Study to Assess the Safety of 
Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered 
by [CONTACT_325362] 
(COPD)
Sponsor Name: [CONTACT_245011]: 151, 85 Södertälje, Sweden
Regulatory Agency Identifier Number(s) 
IND Number: IND118313 
EudraCT Number : [ADDRESS_401713] procedures. The Clinical Study  Protocol  is publicly  registered and the results are 
disclosed and/or published according to the [COMPANY_008] Global Policy  on Bi oethics and in 
compliance wi th prevailing laws and regulat ions.
Redacted for Public Disclosure
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 2of 105Protocol Number: D5985C00003
Amendment Number: Amendment 1.0
Study  Intervent ion: PT010
Study  Phase: III
Short Title: A Study  to Assess the Safet y of Budesoni de/Glycopy rronium/Form oterol  
Fumarate with the Hy drofluorool efin Propellant in Participants with Mo derate to Very  Severe 
Chronic Obstructive Pulmo nary Disease
International co- ordinating investigator (ICI)
Name: 
[CONTACT_325420]:
Study Physician Name [CONTACT_9352] [CONTACT_325363] -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 3of 105SUMMARY OF CHANGES T ABLE
DOCUMENT HISTORY
Document Date
CSP Version 2.0 14 December 2023
CSP Version 1.0 03 June 2022
CSP Version 2.0 , 14 December 2023
This modificat ion is considered to be substant ial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council o f the EU and in the EU 
CTR Article 2, 2 (13).
Overall Rationale for the Modification:
The CSP has been amended primarily  to com ply wit h EU CTR requirements for drug abuse 
and misuse handling, SAE reporting, data archiving and breach reporting, and study  resul ts 
submissio ns to tri al registri es. TheCSP has also been revised to remove the planned clinical 
data l ockafter 12 weeks of treatment. The study will now be unblinded only once at the end of 
the study  (after the l ast subject com pletes the 52 -week treatment period ). Both the 12 -week 
analysis and the 52- week analysis will be co mpleted after unblinding occurs at the end of the 
52-week treatment period.
A summary  of changes is presented below. Where applicable, the changes were also applied 
to the synopsis.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 4of 105Summary of Changes:
List of Substantial Modifications
Section Number and Name [CONTACT_325421] 1.1
Synopsis
Section 4.1
Overall DesignRem oved interim 12 -week c linical data 
lock.To simplify logistics of 
maintaining the double blind 
through the 52-week treatment 
period. Separate blinded and 
unblinded study teams (at 
AstraZ eneca and at its 
representatives performing data 
analy sis) are no longer required 
in order to maintain the blind 
after the 12-week treatment 
period. Only one clinical data 
lock will occur, after the last 
participant completes [ADDRESS_401714] of Non -substantial Modifications
Section Number and Name [CONTACT_325422] “treatment -emergent” as AE 
descriptor.To align with global company 
standard for data outputs.
Section 1.3
Schedule of Activities
Section 8.2.4
ECGs and Holter Monitoring…Added measures implemented to 
standardize ECG/Holter data acquisition 
and interpretation via centrally -provide d 
device ty pe and centralized assessment. 
Clarified this addition in new footnote o 
of Schedule of Activities.Clarification
Section 4.1.[ADDRESS_401715] of acceptable contraception 
methods.
Section 6.1.1
Investigational ProductsAdded description of how investigational 
products will be supplied.Global company requirement
CCI
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 5of 105Section Number and Name [CONTACT_19523] 6.3
Measures to Minimize Bias: 
Randomization and BlindingAdded description of blinding 
procedures.Addition of blinding procedures 
is for comp leteness of CSP; 
details of blinding and blind-
breaking processes were 
previously provided to sites in 
IRT manual. No changes to the 
procedures have been made.
Section 6.5.[ADDRESS_401716] table (restricted 
concomitant medications).Clarification
Section 7.1
Discontinuation of Study 
Intervention
Section 8.2.4
ECGs and Holter Monitoring…Specified that safety evaluations of 
changes in 12-lead ECG and eGF R 
should be made relative to the Visit [ADDRESS_401717]-bronchodilator spi[INVESTIGATOR_23889] 2 
should be performed (it should not be 
viewed as optional).Clarification
Section 8.3.5
Adverse Events Based on 
Examinations and TestsAdded procedure for reporting abnormal 
findings from 12 -lead ECG and from 
digital 12 -lead Holter ECG.Clarification
Section 8.3.8
Reporting of Serious Adverse 
EventsSpecified that the reference document for 
definiti on of expectedness/listedness is 
the IB for both the [COMPANY_008] 
investigational product and the 
[COMPANY_008] active comparator.Clarification
Section 8.3.10
Medication Error, Drug Abuse, 
and Drug Misuse
Appendix B 4
Medication ErrorAdded detailed Drug Ab use and Drug 
Misuse definition and examples.Update required to comply with 
EUCTR.
Section 9.4.3
Safety Analysis
Section [IP_ADDRESS]
Adverse EventsChanged planned presentation of AEOSIs 
to include exposure -adjusted incidence 
rate.Clarification
Section [IP_ADDRESS]
12-lead ECGUpdated definition of baseline to the
mean of the last available triplicate 
measurements extracted from the Holter 
monitor up to 60 minutes prior to dosing 
at Visit 3.Corrected baseline definition to 
align with planned analysis
method as described in the SAP. 
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 6of 105Section Number and Name [CONTACT_19523] [IP_ADDRESS]
Digital [ADDRESS_401718] baseline 
definition.
Section [IP_ADDRESS]
Clinical laboratory valuesClarified definition of baseline to last 
available value prior to dosing on day of 
or prior to randomization.Clarification to increase
flexibility in baseline value 
acquisition.
Section [IP_ADDRESS]
Vital signsUpdated definition of baseline to last 
available value prior to dosing on day of 
or prior to randomization.Corrected baseline definition to 
align with SAP and clarified to 
increase flexibility in baseline 
value acquisition.
Appendix A 1
Regulatory and Ethical 
ConsiderationsAdded sub -section “Regulatory Repo rting 
Requirements for Serious Breaches”.Update required to comply with 
EUCTR and global company 
requirement.
Appendix A 4
Data ProtectionAdded further detail relating to handling 
of personal data breaches.Update required to comply with 
EUCTR.
Appendix A 6
Dissemination of Clinical Study 
DataUpdated information about submission of 
trial results summaries to registries 
including EU CTIS.Update required to comply with 
EUCTR.
Appendix A 7
Data Quality AssuranceUpdated information about retenti on 
timelines of records and documents (25 
years after study archiving or as required 
by [CONTACT_427]).Update required to comply with 
EUCTR and global company 
requirement.
Appendix B 4
Medication Error, Drug Abuse, 
and Drug MisuseDeleted inapplicable table of AE intensity 
grading scales not used in this study.Clarification
Appendix D 2
Genetic Research Plan and 
ProceduresCorrected timing of genetic research 
blood collection to Visit 3 after 
randomization.Alignment with SoA and other 
sections of the CSP.
Appendix F
Changes Related to Mitigation 
of Study Disruptions Due to 
Cases of Civil Crisis, Natural 
Disaster, or Public Health CrisisInserted hy perlinks to cross -referenced 
CSP sections regarding rescreening 
procedures.Clarifi cation
Appendix G Rem oved “eDiary” entry from List of 
Abbreviations.Clarification
Throughout Minor editorial and document formatting 
revisions.Minor, therefore have not been 
summarized.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 7of 105TABLE OF CONTENTS
TITLE PAGE ........................................................................................................................ 1
SUMMARY OF CHANGES T ABLE ................................................................................... 3
TABL E OF CONTENTS ...................................................................................................... 7
1 PROTOCOL SUMMARY ................................................................................ 11
1.1 Synopsis ........................................................................................................... 11
1.2 Schema ............................................................................................................. 15
1.3 Schedule of Ac tivities....................................................................................... 16
2 INTRODUCTION ............................................................................................ 23
2.1 Study  Rati onale ................................................................................................ 23
2.2 Back ground ...................................................................................................... 23
2.3 Benefit/Risk Assessment ................................................................................... 24
2.3.1 Risk Assessment ............................................................................................... 25
2.3.2 Benefit Assessment ........................................................................................... 25
2.3.3 Overall Benefit: Risk Conclusio n...................................................................... [ADDRESS_401719] yle Considerat ions................................................................................... 36
5.4.1 Caffeine, Alcoho l, and Tobacco ........................................................................ 36
5.4.2 Activity............................................................................................................. 36
5.5 Screen Failures ................................
................................................................. 36
6 STUDY INTERVENTION ............................................................................... 38
6.1 Study Intervent ion(s) Administered .................................................................. [ADDRESS_401720] igational Products .................................................................................... 38
[IP_ADDRESS] HFO excipi[INVESTIGATOR_841] .................................................................................................. 39
[IP_ADDRESS] HFA excipi[INVESTIGATOR_841] .................................................................................................. 39
6.1.2 Medical Devices ............................................................................................... 40
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 8of 1056.1.3 Active Pharmaceut ical Ingredient (API): BGF (PT010) Triple Co mbinat ion 
Dose ................................................................................................................. 40
[IP_ADDRESS] Budesonide ....................................................................................................... 40
[IP_ADDRESS] Glycopy rroni um................................................................................................ 40
[IP_ADDRESS] Form oterol  fumarate ......................................................................................... 40
6.2 Preparati on/Handling/Storage/Accountabilit y................................................... 40
6.3 Measures to Minimize Bias: Rando mizat ion and Blinding ................................ 41
6.4 Study  Intervent ion Compliance ......................................................................... 42
6.5 Concomitant Therapy ........................................................................................ 43
6.5.1 Permi tted During the Course of the Study ......................................................... 43
6.5.2 Prohibited Medications ..................................................................................... 43
6.5.3 Restricted Medicat ions...................................................................................... 44
6.5.4 Rescue Medicine ............................................................................................... 45
[IP_ADDRESS] SABA ............................................................................................................... 45
6.6 Intervention After the End of the Study ............................................................. 45
7 DISCONTINUATION OF S TUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITH DRAWAL .......................................................... [ADDRESS_401721] (CAT) ...................................................... 49
8.2 Safety Assessments ........................................................................................... 49
8.2.1 Physical Examinat ions...................................................................................... 49
8.2.2 Vital Signs........................................................................................................ 49
[IP_ADDRESS] Weight and height ............................................................................................. 50
8.2.3 Smoking Status ................................................................................................. 50
8.2.4 Electrocardiograms and Ho lter Monitoring - 24- Hour Continuous 
Electrocardiography .......................................................................................... 50
8.2.5 Spi[INVESTIGATOR_038]........................................................................................................ 51
8.2.6 Clinical Safety  Laboratory  Assessments ............................................................ 52
[IP_ADDRESS] Hem atology...................................................................................................... 54
[IP_ADDRESS] Clinical chemistry ............................................................................................. 54
[IP_ADDRESS] Pregnancy test ................................................................................................... [ADDRESS_401722] .................................................................... 57
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D598 5C00003
CONFIDENTIAL AND PROPRIETARY 9of 1058.3.6.1 Paradoxi cal bronchospasm ................................................................................ 58
[IP_ADDRESS] Level o f COPD severit y by [CONTACT_325364]................................................... 58
[IP_ADDRESS] COPD exacerbat ion assessment ........................................................................ 58
8.3.7 Disease Under Study ......................................................................................... 60
8.3.8 Reporting of Serious Adverse Events ................................................................ 60
8.3.9 Pregnancy ......................................................................................................... 61
[IP_ADDRESS] Maternal exposure ............................................................................................ 61
[IP_ADDRESS] Paternal  exposure .............................................................................................. 62
8.3.10 Medicat ion Error , Drug Abuse, and Drug Misuse .............................................. 62
[IP_ADDRESS] Timelines .......................................................................................................... 62
[IP_ADDRESS] Medicat ion Error ............................................................................................... 62
[IP_ADDRESS] Drug Abuse ...................................................................................................... 62
[IP_ADDRESS] Drug Mi suse ..................................................................................................... 62
8.3.11 Medical Device Deficiencies ............................................................................. 63
[IP_ADDRESS] Time period for detecting Medical Device Deficiencies .................................... 63
[IP_ADDRESS] Follow-up of  Medical Device Deficiencies ....................................................... 63
[IP_ADDRESS] Prom pt reporting of Medical Device Deficiencies to Sponsor ............................ 63
[IP_ADDRESS] Regulatory  reporting requi rements for Medical Device Deficiencies ................. 64
8.4 Overdose .......................................................................................................... 64
8.4.1 Budesonide ....................................................................................................... 64
8.4.2 Glycop yrronium................................................................................................ 65
8.4.3 Form oterol ........................................................................................................ 65
8.5 Optional Genomics Ini tiative Sample ................................................................ 65
9 STATISTICAL CONSIDER ATIONS ............................................................... 66
9.1 Statistical Hypotheses ....................................................................................... 66
9.2 Sample Si ze Determinat ion............................................................................... 66
9.3 Popul ations for Analyses .................................................................................. 66
9.4 Statistical Analyses ........................................................................................... 66
9.4.1 General Considerations ..................................................................................... 67
9.4.2 Efficacy Analysis .............................................................................................. 67
[IP_ADDRESS] Exploratory  CAT assessment ............................................................................ 67
9.4.3 Safety Analysis ................................................................................................. 67
[IP_ADDRESS] Adverse events .................................................................................................. 68
[IP_ADDRESS] 12-lead ECG ..................................................................................................... 68
[IP_ADDRESS] Digital 12-lead Ho lter ECG ............................................................................... 68
[IP_ADDRESS] Clinical laboratory  values ................................................................................. 68
[IP_ADDRESS] Vital signs ......................................................................................................... 68
[IP_ADDRESS] Spi[INVESTIGATOR_280804] .................................................................................. [ADDRESS_401723] OF APPENDICES
Appendix A Regulatory , Ethical , and Study  Oversight Consi derati ons......................... 70
Appendix B Adverse Events: Definit ions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting ........................................................................ 78
Appendix C Handling of Human Bio logical  Samples .................................................. 84
Appendix D Optional Genomics Ini tiative Sample ....................................................... 86
Appendix E Medical Device AEs, ADEs, SAEs, SADEs, [LOCATION_003]DEs and Medical 
Device Deficiencies: Definit ions and Procedures for Recording, 
Evaluat ing, Follow -up, and Reporting in Medical Device Studies ............ 89
Appendix F Changes Related to Mitigation of Study  Disrupti ons Due to Cases of 
Civil Crisis, Natural Disaster, or Public Healt h Crisis .............................. 96
Appendix G Abbreviat ions.......................................................................................... 98
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 11of 1051 PROTOCOL SUMMARY
1.1 Synopsis
Protocol Title: A Rando mized, Double -Blind, 12 -Week (wi th an Extensi on to 52 weeks in a 
subset of Participants), Multi -Center Study  to Assess the Safet y of Budesonide, 
Glycopy rroni um, and Form oterol  Fumarate (BGF) Delivered by [CONTACT_325365] (COPD)
Short Title: A Study  to Assess the Safet y of Budesoni de/Glycopy rronium/Form oterol  
Fumarate with the Hy drofluorool efin Propellant in Participants with Moderate to Very  Severe 
Chronic Obstructive Pulmo nary Disease
Rationale:
A cri tical com ponent of a pressurized metered -dose inhalers (MDIs) formulat ion is the 
propellant (liquified co mpressed gas) which facilit ates actuati on of  the device and subsequent 
delivery  of the pharmaceut ical ingredient(s). Hy drofluoroal kane s (HFAs) were introduced into 
MDI applicat ions beginning with Provent il-HFA in 1994. Prior to HFAs, hydrofluorocarbons 
(HFCs) (or chlorofluorocarbons [CFCs]) were used in MDIs but were replaced in order to 
address concerns about their ozone -depleting prope rties. Current ly used propellant gases 
include HFA -134a and HFA -227ea. Since their introduction, HFA -MDIs have been safely  
used by [CONTACT_325366], primarily for the purpose of treating respi[INVESTIGATOR_325308]. 
While MDI use accounts for a ve ry small  proportion of gl obal HFA emissio ns, it is desi rable 
to repl ace the currently used propellant gases with more environment- friendly  alternatives, 
without com promising pat ient outcomes. [COMPANY_008] is therefore evaluat ing an alternat ive 
propellant (H FO-1234ze). This propellant has a near -zero Global Warming Potential (GWP) 
and very  low photochemical  react ivity. In addit ion, it has very  similar physical properties to 
HFA134a which will ensure co mparable performance o f the delivery  of the BGF dose in th e 
MDI product.
To assess safet y and tol erabili ty, and to continue the effective delivery  of the m etered BGF 
dose, all part icipants (with moderate to very  severe COPD) will receive eit her the near -zero 
GWP HFO1234ze (BGF MDI HFO) 320/14.4/9.[ADDRESS_401724] BGF MDI 
hydrofluoroalkane (HFA) 320/14.4/9.6 µg. Hence the only difference between treatment arms 
in this study  is the propellant.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 12of 105Objectives and Endpoints
Objectives Endpoints
Primary
To assess the safet y and tol erabilit y of 
BGF MDI HFO as compared to BGF 
MDI HFA over 12 to 52 weeks in 
participants wi th moderate to very  severe 
COPDAEs (including SAEs, DAEs, AEOSIs, 
non-serious AEs) 
Digital 12-lead Ho lter electrocardi ogram  
(ECG) 
12-lead ECG
Clinical laboratory  testing
Vital signs
Exploratory
To assess the safet y and tol erabilit y of 
BGF MDI HFO co mpared to BGF MDI 
HFA over 12 to 52 weeks in participants 
with moderate to very  severe COPDChange from pre -dose value in FEV1 at 
5, 15, 30, and [ADDRESS_401725] dose
To expl ore the effect of BGF MDI HFO 
compared to BGF MDI HFA over 12 to 
52 weeks on respi[INVESTIGATOR_325309]Change from baseline COPD Assessment 
Test (CAT) at 12 and 52 weeks
Abbreviations: AEs =adverse events; AEOSIs =adverse event of special interest; BGF =budesonide, 
glycopy rronium, and formoterol fumarate; CAT = COPD Assessment Test; COPD =chronic obstructive 
pulmo nary disease; DAE =discontinuation due to AE; ECG =electrocardiogram; HFA =hydrofluoroalkane; 
HFO =hydrofluoroolefin; MDI =metered -dose inhaler.
Overall Design
This is a Phase 3 randomized, double -blind, 12 -week (with an extensio n to 52 weeks in a 
subset of participants) study  com paring the safet y of BGF MDI HFO 320/14.4/9.6 µg twi ce 
daily  (BID) wi th BGF MDI HFA 320/14.4/9.[ADDRESS_401726] ory of COPD as defined by  [CONTACT_325367] -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 13of 105Thoracic Societ y (ATS) and European Respi[INVESTIGATOR_3764]  (ERS) or by  [CONTACT_325368]. Parti cipants are required to have a forced expi[INVESTIGATOR_325310] 
(FEV1) /forced vital capacit y (FVC) rati o of less than 0.70, and a post -bronchodilator FEV1 ≥ 
25 to < 80% predicted normal value (ie, moderate to very  severe COPD) and be current or 
former smokers wi th a history  of at least 10 pack -years of cigarette smoking. Par ticipants are 
also requi red to be receiving inhaled corticosteroid/long -acting beta2 -agoni st (ICS/LABA), 
long-acting muscarinic antagonist (LAMA)/LABA or ICS/LAMA/LABA inhaled 
maintenance therapi[INVESTIGATOR_014].
At Visit 1, participants continue taking any current COPD maintenance medicat ions. All 
participants will receive Sponsor -provided SABA, albuterol, or salbutamo l for rescue use 
throughout the screening. 
At Visit 3, participants meet ing all inclusio n criteria and none of the exclusio n criteria will  be 
rando mized to BGF HFO 320/14.4/9.6μg or BGF HFA 320/14.4/9.6μg in a 1:1 ratio. All 
participants will receive Sponsor -provided albuterol/salbutamo l for rescue use (Section 6.5.4 ).
Study  intervent ions (during treatment period) will be orally administered as 2 inhalat ions BID 
(every  morning and evening approximately 12 hours apart). 
Adverse events will be collected at clinic visits and telephone contact [CONTACT_765] s. 
Digital 12-lead Ho lter ECG will be performed at Visit [ADDRESS_401727] (AEOSI) in this study are respi [INVESTIGATOR_325311], cough, dy spnea, wheezing, paradoxical bronchospasm, bronchospasm, and COPD 
exacerbations. If any o f the AEOSI are reported, the participants will be asked about time 
relatedness to inhalat ion.
Paradoxi cal bronchospasm is defined as a reducti on in FEV1 of > 15% from baseline (ie, the 
FEV1 value obtained within 30 minutes prior to study  intervent ion administration) that occurs 
shortly  after dosing wi th associ ated symptom s of wheezing, shortness of breath, or cough. A 
drop in FEV1 > 15% from baseline with associated symptoms should be reported as an AE of 
paradoxi cal bronchospasm. 
Moni toring for paradoxi cal bronchospasm will occur at each in -clinic visit by [CONTACT_15209][INVESTIGATOR_325312] [ADDRESS_401728] -dose. If FEV1 drops > 15% from baseline, 
measurements should be repeated unt il FEV1 values have normalized. Monitoring of FEV1 
will also be done at [ADDRESS_401729] 100 com pleters per arm to support extended study  objectives. 
Disclosure Statement : This is a m ulti-center, double- blind, parallel group treatment study  
with 2arms.
Number of Participants:
A planned total of 542 participants will b e randomized to receive study  treatm ent. From the 
271 participants enro lled in each treatment arm of the init ial 12 -week study , 120 participants 
in each arm  will cont inue (on first -in-study  basis) parti cipat ion in the extended study (52 -week 
treatm ent) to allow for at least 100 participants to complete 52 weeks of treatment. 
Parti cipants in the extended study  will rem ain on randomized treatment.
Note : “Enro lled” means a participant’s, or their legally acceptable representative’s, agreement 
to parti cipate in a clinical study  following com pletion of the informed consent process. 
Potenti al parti cipants who are screened for the purpose of determining eligibilit y for the study , 
but are not randomly assigned/assigned in the study, are considered “screen failures”, unless 
otherwi se specified by  [CONTACT_760] .
Intervention Groups (12 -week and 52 -week):
Initial 12 weeks:
BGF MDI HFO on Day (s)1 through 84 (271 participants).
BGF MDI HFA on Day (s)1 through 84 (271 participants).
Treatment extensio n to 52 weeks (subset of initial parti cipants):
BGF MDI HFO on Days 85 through 364 (120 participants).
BGF MDI HFA on Days 85 through 364 (120 participants).
Parti cipants will remain on study  for a minimum of 16 weeks (including the screening and 
treatm ent peri od and a fo llow-up visi t), to a possible maximum of 56 weeks if the participant 
is included in the extended study .
Data Monitoring Committee: No
Statistical Methods
Analyses will be performed by [CONTACT_13670]. Demographic and baseline 
characterist icsdata will be summarized by  [INVESTIGATOR_24258]. Categori cal variables will be 
summarized using frequency  and percentages, where the denominator for calculat ion is the 
underlying analysis set populat ion unless otherwise specified. Continuous variables will be 
summar ized wit h descriptive statist ics using number of available observat ions, m ean, standard 
deviat ion, median, minimum, and maximum, and quartiles where appropriate.
Clinical S tudy Protocol -2.[ADDRESS_401730] ionary  for Regul atory  Activities (MedDRA) 
preferred term (PT) and sy stem  organ class (SOC), for the Safet y analysis set. The summaries 
for each treatm ent arm  will include the number and percentage of particip ants experi encing 
the event and the number of events. 
For adverse events of special interest (AEOSI) incident rates and the associated 95% 
confidence interval (CI) will be presented. The rate difference between treatment arms and the 
associ ated 95% CIs wi ll also be reported. No formal hypothesis tests will be performed. 
Details will be provided in the statist ical analysis plans.
1.2 Schema
Figure 1 Study Design
Note: Telepho ne contact [CONTACT_325369] y 2 weeks outside of clinic visits following the start of study treatment.
Abbreviations: BGF= budesonide, glycopyrronium, and formoterol fumarate; HFA=hydrofluoroalkane; 
HFO=hydrofluoroolefin; MDI= metered -dose inhaler.

Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 16of 1051.3 Schedule of Activities
Table 1 Schedule of Activities for the 12- week and 52 -week extended study
Study visit 1 2 3 4 5 6Follow -
up TCa7b8b9bUnsch. visit(s)cWD 
visitFollow -
up TCaDetails in 
CSP 
Section or 
Appendix
ScreeningRandom
-ization12-week 
EOT 
visit52-week 
EOT 
visit
Study  Week d, e-2 to -1 -1f0 4 8 12 14 26 40 52As 
required As 
required54
Study  Day g -14 to 
-7 (±2)-7 to -1 
(±2)1 28 (±2) 56 (±5) 84 (±5) 98 (±2) 182 (±7) 280 (±7) 364 (±7)As 
required last dose 
(+7) h 378(±2)
Informed consent XAppendix 
A 3
Inclusion/ exclusion 
criteriaX X XSections 5.1
and 5.2
Verify continued 
eligibilityX X X X X X X XSections 5.1
and 5.2
Routine clinical procedures 
Demography and 
medical/surgical historyXSections 5.1
and 5.2
Smoking status X X X X X X X X X X XSection 
8.2.3
Prior/concomitant 
medication review i X X X X X X X X X X X Section 6.5

Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 17of 105Table 1 Schedule of Activities for the 12- week and 52 -week extended study
Study visit 1 2 3 4 5 6Follow -
up TCa7b8b9bUnsch. visit(s)cWD 
visitFollow -
up TCaDetails in 
CSP 
Section or 
Appendix
ScreeningRandom
-ization12-week 
EOT 
visit52-week 
EOT 
visit
Study  Week d, e-2 to -1 -1f0 4 8 12 14 26 40 52As 
required As 
required54
Study  Day g -14 to 
-7 (±2)-7 to -1 
(±2)1 28 (±2) 56 (±5) 84 (±5) 98 (±2) 182 (±7) 280 (±7) 364 (±7)As 
required last dose 
(+7) h 378(±2)
Spi[INVESTIGATOR_038] X jX X kX kX kX kX kX kX kX kXSection 
8.2.5
Reversibility to albuterol XSection 
8.2.5
Troponin assessment X l Section 
8.2.6
Routine safety measurements 
AEmX X X X X X X X X X X X X Section 8.3
TC AE follow -upmX X X X X X X X X X XSection 
8.3.1
Pregnancy testingnX X X X X X X X X XSection 
8.3.9
Clinical safety laboratory 
assessment (blood)X X X X X XSection 
8.2.6

Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 18of 105Table 1 Schedule of Activities for the 12- week and 52 -week extended study
Study visit 1 2 3 4 5 6Follow -
up TCa7b8b9bUnsch. visit(s)cWD 
visitFollow -
up TCaDetails in 
CSP 
Section or 
Appendix
ScreeningRandom
-ization12-week 
EOT 
visit52-week 
EOT 
visit
Study  Week d, e-2 to -1 -1f0 4 8 12 14 26 40 52As 
required As 
required54
Study  Day g -14 to 
-7 (±2)-7 to -1 
(±2)1 28 (±2) 56 (±5) 84 (±5) 98 (±2) 182 (±7) 280 (±7) 364 (±7)As 
required last dose 
(+7) h 378(±2)
Physical examination X X X X XSection 
8.2.[ADDRESS_401731] 
(CAT)X X X X XSection 
8.1.1
Genomics initiative, 
optional e xploratory 
genetic sampleXAppendix
D

Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 19of 105Table 1 Schedule of Activities for the 12- week and 52 -week extended study
Study visit 1 2 3 4 5 6Follow -
up TCa7b8b9bUnsch. visit(s)cWD 
visitFollow -
up TCaDetails in 
CSP 
Section or 
Appendix
ScreeningRandom
-ization12-week 
EOT 
visit52-week 
EOT 
visit
Study  Week d, e-2 to -1 -1f0 4 8 12 14 26 40 52As 
required As 
required54
Study  Day g -14 to 
-7 (±2)-7 to -1 
(±2)1 28 (±2) 56 (±5) 84 (±5) 98 (±2) 182 (±7) 280 (±7) 364 (±7)As 
required last dose 
(+7) h 378(±2)
Study  intervention administration
Dispense/collect Sponsor -
provided albuterol (as 
needed) qX X X X X X X X X XSection 
6.5.4
Discontinue COPD 
maintenance treatmentX Section 6.5
Restart maintenance 
COPD medication after 
study  intervention has 
been stoppedX rX rX rSection 6.5
Dispense/collect blinded 
study  intervention s X X X X X X X X X Section 6.1
Inhalation technique and 
cleaning training and 
verificationX X X X X X X X X Section 6.1
Medical Device 
deficiency checkX X X X X X X XSection 
8.3.11

Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 20of 105Table 1 Schedule of Activities for the 12- week and 52 -week extended study
Study visit 1 2 3 4 5 6Follow -
up TCa7b8b9bUnsch. visit(s)cWD 
visitFollow -
up TCaDetails in 
CSP 
Section or 
Appendix
ScreeningRandom
-ization12-week 
EOT 
visit52-week 
EOT 
visit
Study  Week d, e-2 to -1 -1f0 4 8 12 14 26 40 52As 
required As 
required54
Study  Day g -14 to 
-7 (±2)-7 to -1 
(±2)1 28 (±2) 56 (±5) 84 (±5) 98 (±2) 182 (±7) 280 (±7) 364 (±7)As 
required last dose 
(+7) h 378(±2)
Administer blinded study 
intervention in clinic X X X X X X X X Section 6.1
a. Follow -up TC is to be at Week 14 (Day 98±2) (applicable only for 12 weeks study participants), Week 54 (Day 378±2) or [ADDRESS_401732] dose, de pending on whether the 
participant completed the 12 week treatment period, 52 week treatment period, or was an early withdrawal.
b. Study  Visits 7, 8 & 9 are only applicable to the 52 -week extended study.
c. Assessments done at Unscheduled Visits are at the discretion of the Principal Investigator (PI). 
d. Risk assessments for the SARS -CoV-[ADDRESS_401733] be made prior to every in -clinic vi sit in line with the Study Disruptions Mitigation Instructions.
e. Sites should call participants 1 to 2 days before each scheduled in -clinic visit to remind them of the upcoming visit and related restrictions/requirements, including 
withholding morning study intervention dose on the day of on -site study  visit.
f. Visit 2 will be scheduled following Visit 1 based on the time to receive the participant’s clinical laboratory results.
g. Site should make every effort to maintain participants within the scheduled visit windows. Participants who fall outside the visit window should be placed in the protocol -
defined window at the next scheduled visit.
h. Withdrawal visit is recommended as soon as possible after last dose, but within [ADDRESS_401734] dose of study intervention and albuterol/salbutamol; if less than [ADDRESS_401735] dose 
of albuterol/salbutamol, the visit should be rescheduled.
j. At Visit [ADDRESS_401736] -dose for safety assessments. See Table 2for a schedule of spi[INVESTIGATOR_31757].
l. Troponin measured only at baseline (Visit 3) prior study intervention administration. Post randomization troponin should be m easur ed according to the Investigator’s 
decision and only when clinically indicated for potential AE diagnosis/reporting.
m. Throughout the study AEs will be captured every [ADDRESS_401737] and/or site visits (telephone: Weeks 2, 6, 10, 14, 16, 18, 20 , 22, 24, 28, 30, 32, 34, 36, 
38, 42, 44, 46, 48, 50, and 54; in -person site visits: Weeks 0, 4, 8, 12, 26, 40, and 52, as well as at any applicable Unscheduled or Withdrawal visits) .
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 21of 105n. Serum/ urine pregnancy testing at Visit 1 and urine pregnancy testing at following visits to be performed for women of childbearing potential. Serum LH and FSH are 
additionally tested (within 21 to 28 days before Visit 3) for women < [ADDRESS_401738] data for both the 12 -lead ECG and the digital 12 -lead Holter ECG (see Section 8.2.4 ).
p. Digital 12 -lead Holter ECG will be connected the day prior to Visit 3 (randomization) and Visit 6 to establish a baseline. At Visit 3 an d 6, 12 -lead extractions of conve ntional 
resting ECG will be done 60 min pre -dose (before spi[INVESTIGATOR_038]) and 20 min, 60 min (before [ADDRESS_401739] -dose spi[INVESTIGATOR_038]) and [ADDRESS_401740] dose (see Table 2for a schedule of 
Holter ECG assessments).
q. Study -provided albuterol/salbutamol is allowed for use as needed throughout the Screening and Treatment Periods.
r. COPD maintenance treatment should be prescribed/initiated at Visit 6 for participants completing the 12- week treatment period and not continuing into the Extended 
treatment period and at Visit 9 for participants completing the 52 -week treatment period.
s. Check puff indicator on returned MDI devices to assess study intervention dosing compliance, document results in medical records/eCRF. Report Overdose for cases 
confirmed by [CONTACT_325370]/she inhaled more than 2 puffs of BGF MDI twice daily, in the morning and in the evenin g.
Abbreviations: AEs =adverse events; CAT =COPD Assessment Test; C OPD =chronic obstructive pulmonary disease; CSP = Clinical Study Protocol; ECG =electrocardiogram; 
EOT = End -of-treatment Visit; FSH = follicle -stimulating hormone test; hr = hour(s); min = minutes; SABA =short -acting beta2 -agonist; TC =telephone conta ct; ‘±’ =within a 
time period (before or after); TC = Telephone contact; Unsch. = Unscheduled Visit(s); WD = Withdrawal.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 22of 105Table 2 Schedule of Activities for Procedures Related to Holter ECG, Spi[INVESTIGATOR_325313]-Visit 3 Visit 3 Pre-Visit 6 Visit 6 Spi[INVESTIGATOR_23922] 4, 5, 
7, 8, 9, and Unsch.
Study Day 0 1b83 (±5) 84 (±5)b28 (±2), 56 (±5), 182 (±7), 
280 (±7), 364(±7), Unsch. 
Holter monitor hook up 
procedureaX X N/A
60 min pre -dose ECG 
(extract f rom Holter)Dose -60 min Dose -60 min N/A
Spi[INVESTIGATOR_038] [ADDRESS_401741] 
dosingDose +5 min Dose +5 min Dose +[ADDRESS_401742] 
dosingDose +15 min Dose +15 min Dose +15 min
ECG +[ADDRESS_401743] f rom 24 Hours 
HolterDose +20 min Dose +20 min N/A
Spi[INVESTIGATOR_038] +[ADDRESS_401744] 
dosingDose +30 min Dose +30 min Dose +30 min
ECG +[ADDRESS_401745] f rom 24 Hours 
HoltercDose +60 min Dose +60 min N/A
Spi[INVESTIGATOR_038] +[ADDRESS_401746] 
dosingDose +60 min Dose +60 min Dose +60 min
ECG +[ADDRESS_401747] f rom 24 Hours 
HolterDose +4 hr Dose +4 hr N/A
a. Participants will need to visit the site 1 day prior to scheduled Visit 3 and Visit 6 for Holter hook up procedure, 
after which the participant may return home or, if justified due to travel distance and following prior approval by 
[CONTACT_2728], alternative lodging close to the site may be provi ded. The suggested time slot for both pre -visits (day 
before Visit 3 and day before Visit 6) is 13:00 (±2 hr).
b. Note: More than 5 hr is needed to complete assessments required by [CONTACT_325371]/SoA, so if Visit 3/6 will start at 07:00, the 
earliest visit would end is 12:00; similarly for other minimal time slots 08:00 to 13:00; 09:00 to14:00, etc. 
c. ECG +[ADDRESS_401748] be done prior to Spi[INVESTIGATOR_038] +[ADDRESS_401749] study intervention 
dosing. 
Abbreviations: CSP = Clinical Study Protocol; ECG =electrocardiogram; hr =hours; min =minutes; N/A = not applicable; 
‘±’=within a time period (before or after); Unsch. = Unscheduled Visit(s).
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 23of 1052 INTRODUCTION
2.1 Study Rationale
The current HFA propellant (study  com parator treatment) is known to ha ve a relat ively high 
GWP co mpared with so me alternative propellants. The reformulat ion of [COMPANY_008]’s MDI 
products wi th HFO have much lower GWP and will allow pat ients to continue to use MDI 
type treatm ents while contribut ing to [COMPANY_008]’s sustainabilit y efforts.
This study  will evaluate the safety  and tol erabilit y of BGF MDI HFO 320/14.4/9.6 µg BID 
compared wi th BGF MDI HFA 320/14.4/9.6 µg BID in participants with moderate to very  
severe COPD over 12 to 52 weeks. The formulat ions to be evaluated in th is study are MDIs 
containing a fixed -dose tri ple combinat ion of budesonide, glycopyrronium, and formoterol 
fumarate, that utilize either the current propellant HFA or HFO with lower GWP. The BGF 
formulations only  differ in the propellant excipi[INVESTIGATOR_325314].
2.2 Background 
Chronic obstructive pulmo nary disease (COPD) is a common progressive disease wit h 
substant ial associated morbidit y and m ortali ty. As many as 384 millio n people glo bally  suffer 
from COPD ( WHO2020). Many o f these pat ients are currently treated using MDIs 
containing propellants that contribute to the global carbon footprint.
The m ost important risk factor for COPD is tobacco smoke and other air po llutants; 
approximately  75% of  COPD deaths are attributed to cigarette smoking, however, [ADDRESS_401750] never smoked ( Wheaton et al 2019 ). Even a single COPD 
exacerbation may be associated with a significant increase in the rate of lung funct ion decline 
and can be associated with reduction in life expectancy ( Halpin et al  2017 ; Suissa et al  2012 )
. 
Well -managed, stable COPD patients have a lower environmental impact than uncontrolled 
patients, who m ay over -use MDI reliever therapi[INVESTIGATOR_325315] ( Usmani et al 2019 ;O'By [CONTACT_129120]  2017 ).
COPD al so has a potenti ally harmful econo mic impact. In 2010, COPD resulted in over 
10millio n office visits, nearly 1.5 millio n emergency  department vi sits, 700,000 
hospi [INVESTIGATOR_36651], and 133,575 deaths in the US ( Ford et al 2013 ). In 2010, US total medical 
treatm ent costs attributed solely to COPD (ie, excluding comorbidit ies) were estimated to be 
$32.1 billio n, wi th an addit ional $3.9 billi on in COPD costs result ing from worker 
absenteeism ( Ford et al  2015 ). Even in industrialized countries such as the US where 
anti
-smoking ini tiatives have been relatively successful, the legacy o f past smoking behavior 
in aging popul ations ensures that the COPD burden will unavo idably continue to climb over 
the next 20 to 30 y ears (Feenstra et al 2001 ) . 
Clinical Study Protocol -2.[ADDRESS_401751] common t ypes o f devices used 
in inhaled m edicines. Inhaled medicines reduce COPD exacerbat ions, which are potentially 
life-threatening events ( Sastre et al 2016 and Beasley  et al  2019 ). Although HFA (and 
previously CFC) propellants have been proven to have minimal adverse effects and are 
currently fit -for
-purpose, they  contain small quant ities o f a type of greenhouse gas (fluorinated
gases), which acts as a heat shield in the Earth’s atmosphere ( Pritchard 2020 ). They  are an 
important device option for pati ents, parti cularly  where familiarit y with the device, limited 
lung funct ion, young or advanced age, reduced dexterit y or cognit ion are considerations 
(Schreiber et al 2020 ).
The next -generat ion MDI to treat COPD should contain a propellant that can deliver a 
metered dose at a similar level o f safet y and tolerabilit y as the currently applied propella nts 
([COMPANY_002] et al 2016 ).Positive action is required to switch to an alternative propellant for MDIs 
with low GWP. The desire to reduce any  impact to the current level of greenhouse gas 
emissio ns is a global ambit ion, but al ternat ive propellants may also reduce manufacturing 
costs, result ing in cost benefits to the patient. An alternative mode of dose delivery is possible 
with dry powder inhalers (DPIs) and Mist inhalers, however, this mode of delivery  is not 
suitable for all  medical  needs and are more expensive to produce ( Wilkinson et al 2019 ). 
Breztri  Aerosphere® ( budesonide/glycopy rronium/f ormoterol  fumarate), a tri ple combinat ion 
therapy  for COPD, i s the fi rst m edicine planned for transit ion to thi s next -generation MDI 
propellant. By  [CONTACT_325372] -generation MDIs, with a near -zero GWP propellant, and DPI 
[INVESTIGATOR_325316], important therapeutic options for patients have the potential to achieve ambit ious 
environmental targets. [COMPANY_008] has made a company -wide commit ment to m eet climate
neutralit y goals through reducing the impact of these propellants on the environment, 
however, it is important to ensure that there is no compromise to patient outcomes. 
2.3 Benefit/Risk Assessment
Budesonide, glycopy rroni um, and form oterol  fumarate are appr oved in many countries 
worldwide in mult iple formulations for different indicat ions, such as the treatment of COPD.
This study  follows fro m study  D5985C00001, an assessment of thepharmacokinetics, safet y,
and tol erabilit y ofafixed -dose combinat ion ofbudesonide, glycopy rroni um, and f ormoterol 
when administered assingle doses in3 different propellant formulat ions in healt hy 
participants. The study  resul ts showed that systemic exposure to budesonide, glycopyrronium, 
and form oterol  was similar for BGF MDI HFO -1234ze (a hydrofluoroolefin propellant) 
compar ed wi th the reference product, BGF MDI HFA -134a (a hydrofluoroal kane propellant), 
and HFC -152a ([CH3CHF2] an al ternative propellant of l ow GWP).
There were no safet y signals observed in Study D5985C00001 when the combinat ion of
budesonide, glycopy rroni um, 
andformoterol were administered assingle doses in3 different
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 25of 105propellant formulat ions. A non-validated scale wasused toevaluate participants’ percepti on 
ofthetaste ofthe [ADDRESS_401752] been minimized in the fo llowing ways:
All participants will be screened and those with any  chronic condi tion that coul d, in th e 
judgment of the Invest igator, represent a risk to safe participation, will be excluded.
Use of Holter ECG, and reliable spi[INVESTIGATOR_325317] m onitor for the onset of AEs.
Parti cipants will be routinely  monitored f or AEs during tel ephone contacts and clinic 
visits.
2.3.1 Risk Assessment
Theinformat ion contained inthis study  isconsistent with curren tknowledge oftherisks and 
benefits of thestudy interventi on; for additional informat ion, refer to the latest product 
Invest igator’s Brochure (IB). Risks, responsibilit ies, and benefits areadditionally  detailed in
theinformed consent form (ICF). For a detailed discussion of the known safet y profile of BGF 
MDI HFO, please refer to the current IB. 
This global study  may be init iated or conducted durin g the SARS -CoV-2 pandemic, another 
civil crisis, natural disaster, or public health crisis; the regional and/or country level risk may 
vary during the conduct of the study. Guidance will be ratified with local regulations, health 
authorit y and relevant pro fessional bodies to minimize the expected direct risks to site 
personnel and study participants. Alternative measures and procedures may be implemented 
during the conduct of the study as described in Section 4.1.1.
 Risk assessments for the 
SARS -CoV -[ADDRESS_401753] of older more environmentally harmful propellants.
2.3.3 Overall Benefit: Risk Conclusion
For the safet y of parti cipants, the protocol has incorporated various risk mit igation measures 
including appropriate inclusio n and exclusio n criteria and close m onitoring of part icipants. 
Clini cal Study Protocol -2.[ADDRESS_401754] ion:
Table 3 Objectives and Endpoints
Objectives Endpoints
Primary
Safety objectives: To assess the safet y 
and tol erabilit y of BGF MDI HFO as 
compared to BGF MDI HFA over 12 to 
52 weeks in participants with moderate 
to very  severe COPDAEs (including SAEs, DAEs, AEOSIs, 
non-serious AEs) 
Digital 12-lead Ho lter electrocardi ogram  
(ECG) 
12-lead ECG
Clinical laboratory  testing
Vital signs
Exploratory
To assess the safet y and tol erabilit y of 
BGF MDI HFO co mpared to BGF MDI 
HFA over 12 to 52 weeks in participants 
with moderate to very  severe COPDChange from pre -dose value in FEV1 at 
5, 15, 30, and [ADDRESS_401755] dose
To expl ore the effect of BGF MDI HFO 
compared to BGF MDI HF A over 12 to 
52 weeks on respi[INVESTIGATOR_325309]Change from baseline COPD 
Assessment Test (CAT) at 12 and 52 
weeks
Abbreviations: AEs =adverse events; AEOSIs =adverse event of special interest; BGF =budesonide, 
glycopyrronium, and formoterol fumarat e; CAT = COPD Assessment Test; COPD =chronic obstructive 
pulmo nary disease; DAE =discontinuation due to AE; ECG =electrocardiogram; MDI =metered -dose inhaler.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 27of 1054 STUDY DESIGN
4.1 Overall Design
The formulat ionsto be evaluated in this study  are MDIs containing a fixed -dose tri ple 
combinat ion of BGF that utilize either the current propellant HFA or HFO with lower GWP. 
The BGF formulat ions only  differ in the propellant excipi[INVESTIGATOR_325318].
This i s a Phase 3 randomized, double -blind, 12 -week (with extensio n to 52 weeks in a subset 
of parti cipants) study  com paring the safet y of BGF MDI HFO 320/14.4/9.6 µg BID with BGF 
MDI HFA 320/14.4/9.[ADDRESS_401756] an established clinical history  of COPD as defined by [CONTACT_325373] (ATS)/European Respi[INVESTIGATOR_96661] (ERS) ( Celli et al 2004 , Loui s et al  2022 ) . 
Parti cipants are requi red to have an FEV1/FVC ratio of <0.[ADDRESS_401757] -bronchodilator FEV1 
≥25 to <80% predicted normal value (ie, moder ate to very  severe COPD) and be current or 
former smokers wi th a history  of at least 10 pack -years of cigarette smoking. Participants are 
also requi red to be receiving ICS/LABA, LAMA/LABA or ICS/LAMA/LABA inhaled 
maintenance therapi[INVESTIGATOR_014].
At Visit 1, particip ants continue taking any current COPD maintenance medicat ions. All 
participants will receive Sponsor -provided SABA consist ing of albuterol or salbutamo l for 
rescue use throughout the screening (refer to Section 6.5.4). 
At Visit 3, participants meet ing all inclusio n criteria and none of the exclusio n criteria will  be 
rando mized to BGF HFO 320/14.4/9.6 μg or BGF HFA 320/14.4/9.6 μg in a 1:1 ratio. All 
participants will receive Sponsor -provided albuterol/salbutamo l for rescue use.
Study  intervent ions (during treatment period) will be orally administered as 2 inhalat ions BID 
(every  morning and evening approximately 12 hours apart). 
Adverse events will be collected at clinic visit s and telephone contact [CONTACT_765] s throughout the 
study . 
Digital 12-lead Ho lter ECG will be performed at Visit [ADDRESS_401758] ions.  
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 28of 105The AEOSIs in this study  are respi [INVESTIGATOR_325319], cough, dyspnea, 
wheezing, paradoxical bronchospasm, bronchospasm, and COPD exacerbat ions. If any o f the 
AEOSI are reported, the participants will be asked about time relatedness to inhalat ion.
Paradoxi cal bronchospasm is defined as a reduction in FEV1 of > 15% from baseline (ie, the 
FEV1 value obtained within 30 minutes prior to study  intervent ion administration) that occurs 
shortly  after dosing wi th associ ated symptom s of wheezing, shortness of breath, or cough. For 
the purpose of this study , a drop in FEV1 > 15% from baseline at 5 and/or [ADDRESS_401759] -dose. If FEV1 drops > 15% from baseline, 
measurements should be repeated unt il FEV1 values have normalized. Monitoring of FEV1 
will also be done at [ADDRESS_401760] Mitigation Dur ing Study Disruptions Due to Cases of 
Civil Crisis, Natural Disaster, or Public Health Crisis
The gui dance given below supersedes instructions provided elsewhere in this Clinical Study  
Protocol  (CSP) and should be implemented only during cases of civil cri sis, natural  disaster, 
or public healt h crisis (eg, during quarant ines and result ing site closures, regional travel 
restri ctions, and considerations if site personnel or study participants beco me infected with 
SARS -CoV -2 or similar pandemic infection) whic h would prevent the conduct of 
study -related activit ies at study  sites, thereby  [CONTACT_325374]’s abilit y to conduct the study . The Investi gator or desi gnee shoul d contact [CONTACT_429]/CRO to discuss whether the mit igation plans below should be implemented.
To ensure continuit y of the clinical study  during a civil crisis, natural disaster, or public healt h 
crisis, changes m ay be implemented to ensure the safet y of study  parti cipants, maintain 
compliance wi th Good Clinical Practi ce (GCP), and minimize risks to study  integrity.
Where allowable by  [CONTACT_122593], ethi cs commi ttees, heal thcare provi der gui delines 
(eg, hospi[INVESTIGATOR_13338]) or local government, these changes may include the fo llowing opti ons: 
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 29of 105Obtaining reconsent for the mit igation procedures 
(Note: in the case of verbal consent/reconsent, the ICF should be signed at the participant’s 
next contact [CONTACT_72953]).
Rescreening: Addit ional rescreening for screen failure and to confirm eligibilit y to participate 
in the clinical study  may be perform ed in previously  screened participants. The Investigator 
shoul d confi rm this wi th the Sponsor/CRO’s designated Medical Monitor. If rescreening takes 
place wi thin [ADDRESS_401761] (RT -PCR) for COVID -19 at screening may be 
rescreened after 12 weeks (3 months) provided that there is no development of severe 
COVID -[ADDRESS_401762] ion or sequalae.
Hom e or rem ote vi sit: Perf ormed by a site qualified Health Care Professio nal (HCP) or HCP 
provi ded by a third -party  vendor (TPV).
Telemedicine visit: Remote contact [CONTACT_325375], virtual or video visit s, and m obile heal th devices.
Hom e intervent ion supplies in case on -sitevisit is not possible due to COVID -19 site 
issues/logist ics. Visit can be done remotely as TC or Video call.
For further details on study  conduct during civil crisis, natural disaster, or public health crisis, 
refer to Appendix F.
4.2 Scientific Rationale for Study Design
The suitabilit y of HFO- 1234ze as an alternat ive propellant to HFA134a in the BGF MDI 
320/14.4/9.6 μg formulat ion will be assessed in this clinical stud y. All other form ulation 
components will remain the same. The components of the container closure system (MDI) 
used to deliver the formulation to the participant will also remain unchanged. The drug 
product formulat ion containing HFO1234ze should be stored according to the instructions on 
the label and the instruction for use (IFU).
All completed non -clinical studi es conducted to date were designed to evaluate the toxico logy 
(including safet y pharmaco logy) and are described below. Unless otherwise stated, all studies 
were conducted via inhalat ion exposure. The preclinical species used (mouse, rat, rabbit, and 
dog) were chosen as they  are recognized as appropri ate non -clinical species to predict 
toxicological change in man and are acceptable to regulatory  agencies. Due to absence of 
pharmaco logical act ivity of HFO -1234ze (as with exist ing propellant gases), limit ed 
pharmacokinet ic or metabo lism studies have been conducted.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 30of 1054.3 Justification for Dose
The BGF dose approved for the treatment of COPD, is 2 inhalation s twi ce daily 
(320/14.4/9.6 µg [BID]). Each dose of the propellant to which participants will be exposed, 
will thus reflect a 12 -hour cycle which will be part of the 2 inhalat ions twice daily dosage of 
BGF.
In thi s clinical study , parti cipants will receive BGF treatm ent including ei ther the HFO or 
HFA propellant gas. Participants will receive 2 BGF inhalat ions twi ce daily , including an 
emitted dose of 58.6 mg HFO -1234ze/actuation, or 1.95 mg/kg twice daily, assuming a [ADDRESS_401763]-Levels (NOELs) and/or No -Observable -Adverse -Effect-Levels 
(NOAELs) identified in repeat dose and reproductive toxico logy studi es have shown safet y 
margins at > 1000 times a dose of 1.95 mg/kg BID.
Based on data for HFA -134a (a structurally related gas cu rrently used as a propellant in 
MDIs), HFO -1234ze would be expected to be cleared fro m the circulati on very  rapi[INVESTIGATOR_325320]. 
Preclinical exposure data with HFA -134a showed an est imated half -life of no more than 
7minutes in preclinical st udies ( Alexander et al 1995 ).
4.4 End of Study Definition
For the purpose of Clinical Trial Transparency
,the definit ion of the end of the study  differs 
under FDA and EU regulatory  requi rements:
European Unio n requirements define study  com pletion as the l ast vi sit of the l ast subject for 
any protocol -related activit y.
Food and Drug Administration requirements define two c ompletion dates:
Primary Co mpletion Date –the date that the final participant is examined or receives an 
intervent ion for the purposes of final co llection of data for the primary  outcom e measure, 
whether the clinical study  concluded according to the pre -specified protocol or was 
terminated. In the case of clinical studies with more than one primary outcome measure with 
different complet ion dates, this term refers to the date on which data collect ion is completed 
for all of the primary  outcom es.
Study  Com pletion Date –the date the final part icipant is examined or receives an intervent ion 
for the purposes of final co llection of data for the primary  and secondary outcom e measures 
and AEs (for example, the last participant’s last visit), whether the clinical study  concludes 
according to the pre -specified protocol or is terminated.
Clinical Study Protocol -2.[ADDRESS_401764] scheduled procedure shown in the SoA ( Table 1) .
The study  will end when the last remaining participant fro m approximately  100 parti cipants 
per treatment arm co mpletes his/her Week 52/Visit  [ADDRESS_401765]. If study  interventi on is discont inued prior to the Week 52/Visit 9, then 
study  will end at the com pletion of the Wit hdrawal Visit and subsequent [ADDRESS_401766].
Parti cipants contribut ing only to the 12 weeks safety stud y will need to complete their 
Week 12/Vi sit [ADDRESS_401767]. If study  intervent ion 
was discont inued prior to the Week 12/Visit 6, then study will end at the completion of the 
Withdrawal Visit and subsequent [ADDRESS_401768].
5 STUDY POPULATION
The PI [INVESTIGATOR_325321] a screening log of all potential participants who consent and are 
subjected to screening procedures. Participants who fail to meet the inclusio n criteria or m eet 
any of the exclusio n criterion are refused entry  into the study . There are no except ions to this 
rule. One repeat assessment can be requested at the discret ion of the PI (including any 
laboratory  tests, ECG m easurements or vital sign measurements) at the screening visit and on 
admissio n to the study  center.
5.1 Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criteria apply:
Age
1.Parti cipant m ust be 40 to 80 y ears of age inclusive, at the time of signing the ICF;
Type of Participant and Dise ase Characteristics
2.Parti cipants who have a docum ented history  of physician -diagnosed COPD as defined by  
[CONTACT_58286]/ERS ( Celli et al 2004 ) or by  [CONTACT_325376];
3.Parti cipants who have been regularly using dual ICS/LABA, LAMA/LABA, or 
ICS/LAMA/LABA (open or fixed -dose com binat ions) inhaled maintenance therapi[INVESTIGATOR_325322] 6 weeks prior to Screening;
4.Parti cipants who have pre -
bronchodilator FEV1 of < 80% predicted normal at Visit 1;
5.Parti cipants who have post -bronchodilator FEV1/FVC ratio of < 0.[ADDRESS_401769]-bronchodilator FEV1 of ≥ 25% to < 80% predicted normal at Visit 2;
6.Parti cipants who have CAT score ≥ 10 at Visit 1;
7.Parti cipants who are current/former smokers wit h a history  of at least 10 pack -years of 
tobacco smoking (1 pack y ear = 20 cigarettes smoked per day  for 1 y ear);
Clinical Study Protocol -2.[ADDRESS_401770] current 
COPD therapy , as requi red by  [CONTACT_760] ;
9.Parti cipants m ust be able to dem onstrate acceptable MDI administration and spi[INVESTIGATOR_325323];
10.Parti cipants who are willing to rem ain at the study  center as required per protocol to 
complete all  visit assessments;
Sex
11.Females must either be not of childbearing potential, or using a form of highly effective 
birth control as defined below:
oWomen not of childbearing potential ar e defined as women who are either 
perm anent ly sterilized (hysterectomy, bilateral oophorectomy, or bilateral 
salpi[INVESTIGATOR_1656] ), or who are postm enopausal . Women will be considered 
postm enopausal if they  have been amenorrhoei c for 52 weeks (12 months) 
prior to the planned date of rando mizat ion without an al ternative m edical 
cause. The fo llowing age -specific requirements apply:
oWomen < [ADDRESS_401771] been 
amenorrhoei c for 52 weeks (12 months) or more following cessat ion of 
exogenous hormonal treatment and fo llicle st imulating hormone levels in the 
postm enopausal range.
oWomen ≥ [ADDRESS_401772] been 
amenorrhoei c for 52 weeks (12 months) or more following cessat ion of all 
exog enous horm onal treatm ent.
12.Female participants of childbearing potential must use one highly effect ive form of birth 
control . A highly  effect ive method of contraception is defined as one that can achieve a 
failure rate of less than 1% per y ear when used con sistent ly and correctly. At enrollment, 
wom en of childbearing potential who are sexually active wit h a non -sterilized m ale 
partner should be stable on their chosen method of highly effect ive birth control, as 
defined below, and willing to remain on the bir th control  until at least [ADDRESS_401773] 
dose of study  intervent ion. Cessat ion of contraceptio n after this point should be discussed 
with a responsible physician. Periodic abstinence (calendar, symptothermal, post -
ovulation methods), withdrawal (coitus interruptus), spermicides only , and lactati onal 
amenorrhea m ethod are not acceptable methods of contraception. Female condom and 
male condo m shoul d not be used together.
oAll wo men of childbearing potential must have a negative serum pregnancy 
test result at Visit 1
oWomen <[ADDRESS_401774] (within 21 -28 days before 
Visit 3) f or study eligibilit y
Highly effect ive birth control methods are listed below:
Clinical Study Protocol -2.[ADDRESS_401775] yle of the 
participant.
oCombined (estrogen and progestogen containing) hormonal contraception 
associ ated wi th inhibit ion of ovulat ion:
oOral
oIntravaginal
oTransdermal
oProgestogen -only hormonal contracepti on associ ated wi th inhibition of 
ovulation:
oOral
oInjectable
oImplantable
oIntrauterine device or intrauterine hormone -releasing system
oMale partner sterilizat ion/vasectomy  with docum entati on of  azoospermia prior 
to the female participant’s entry  into the study , and this m ale is the sole partner 
for that parti cipant. The documentation on male sterilit y can co me from the site 
personnel’s review of participant’s medical records, medical examinat ion 
and/or sem en analysis or medical history  interview provided by  [CONTACT_325377].
oBilateral tubal ligat ion
Informed Consent
13.Capable of giving signed informed consent as described in Appendix Awhich incl udes 
compliance wi th the req uirements and restri ctions listed in the ICF and in this protocol.
5.2 Exclusion Criteria 
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply: 
Medical Conditions
1.Parti cipants who have a docum ented history  of physician -diagnosed a sthma in the opi[INVESTIGATOR_3078] n 
of the Invest igator based on thorough review of medical history and medical records, 
within 5 years of Visit 1;
2.Parti cipants who have COPD due to α1 -Antitrypsin Deficiency; 
3.Parti cipants wi th histori cal or current evi dence of a clinica lly significant disease 
including, but not limited to: cardiovascular, hepatic, renal, hematological, neuro logical, 
Clinical Study Protocol -2.[ADDRESS_401776] the efficacy or safet y 
analyses;
4.Sleep apnea that, i n the opi[INVESTIGATOR_3078] n of the Invest igator, cannot be controlled;
5.Other respi [INVESTIGATOR_325324], lung cancer, cy stic 
fibrosis, significant bronchiectasis (high reso lution CT evi dence of bronchiectasis that 
causes repeated acute exacerbat ions), immune deficiency disorders, severe neurological 
disorders affecting control of the uppe r airway, sarcoi dosis, i diopathic intersti tial 
pulmo nary fibrosis, primary  pulm onary hypertension, or pulmo nary thromboembolic 
disease;
6.Parti cipant wi th moderate or severe COPD exacerbat ion or respi [INVESTIGATOR_325325] 4 weeks pri or to Visit 1 or during the Screening period;
7.Parti cipant who has had a SARS- CoV -[ADDRESS_401777] ion in the 8 weeks prior to Visit 1 or during 
the Screening Period or that required hospi[INVESTIGATOR_325326] 1 or during 
the Screening Period;
8.Pulmo nary resecti on or lung vo lume reduct ion surgery  during the 26 weeks (6 months) 
prior to Visit 1 (ie, lobectomy, bronchoscopy  lung vo lume reduction [endobronchial 
blockers, airway by[CONTACT_6476], endobronchial valves, thermal vapor ablation, bio logical 
sealants, and airway implants ]); 
9.Long -term oxygen therapy; 
10.Imminent life -threatening COPD (eg, need for mechanical vent ilation);
11.Parti cipant who has si gnificant or unstable ischemic heart disease, arrhy thmia, 
cardi omyopathy , heart failure, uncontrolled hypertension as defined by  [CONTACT_286022], 
or any  other rel evant cardi ovascular disorder as judged by [CONTACT_24342];
12.Parti cipant wi th narrow angl e glaucoma not adequately treated and/or change in visio n 
that may  be relevant, in the opi[INVESTIGATOR_66286];
Note: All medicat ions approved for control of intraocular pressures are allo wed including 
topi[INVESTIGATOR_325327]
-blockers and prostaglandin analogs.
13.Symptom atic prostatic hypertrophy  or bl adder neck obstructi on/urinary  retent ion that, in 
the opi [INVESTIGATOR_689], is clinically significant;
Note: Participants with trans -urethral  resect ion of prostate or full resect ion of the prostate 
within 26 weeks (6 months) prior to Visit [ADDRESS_401778] 5 y ears pri or to 
Visit 1;
Note: Squamous cell and basal cell carcino mas of the skin are not exclusio nary
Prior/Concomitant Therapy
15.Known history  of drug or al coho l abuse within 52 weeks (12 months) of Visit 1;
Clinical Study Protocol -2.[ADDRESS_401779] ion testing 
at each applicable study  visit;
17.Parti cipant i s unable to abstain from protocol -defined prohibited medicat ions during 
Screening and Treatment Periods;
18. Using any herbal products either b y inhalat ion or nebulizer within 2 weeks of Visit 1 and 
does not agree to stop for the duration of the study;
19.Parti cipants wi th a known hypersensit ivity to beta2 -agoni sts, m uscarinic antagonists, or 
corticosteroi ds, or any  com ponent of the MDI;
Prior/Concu rrent Clinical Study Experience
20.Parti cipation in another clinical study  with an intervent ion administered in the last 30 
days or 5 half -lives, whichever is longer;
21.Previous rando mizat ion in any study  using BGF MDI HFO 
(budesonide/glycopy rroni um/f ormoterol  fumarate – HFO);
Diagnostic Assessments
22.Parti cipants wi th calculated eGFR ≤ 30 mL/minute/1.73m2using the Chronic Kidney  
Disease Epi [INVESTIGATOR_325328] (CKD- EPI) form ula;
23.Any clinically  relevant abnorm al findings in physical examinat ion, clinical chemi stry, 
hematol ogy, vital signs, or ECG, whi ch in the opi[INVESTIGATOR_3078] n of the Invest igator, may put the 
participant at risk because of his/her participation in the study;
Note: Participants with ECG QTcF interval (corrected for heart rate using Fridericia’s 
formula [QTcF]) > [ADDRESS_401780] ion with clinically  significant 
pauses who are not treated with pacemaker will also be excluded.
Other Exclusions
24.Planned hospi [INVESTIGATOR_16366];
25.Involvement in the planning and/or conduct of the study (applies to both [COMPANY_008] 
staff and/or staff at the study  site);
26.Study  Invest igators, sub -Invest igators, coordinators, and their emplo yee or immediate 
family members;
27.Judgment by  [CONTACT_325378] h study  
procedures, restrict ions and requirements;
28.For wom en only –current ly pregnant (confirmed with positive pregnancy test), breast 
feeding, or planned pregnancy during the study  or wom en of childbearing potential not 
using acceptable contraception measures (see Inclusion criterion 12in Sect ion 5.1).
Clinical Study Protocol -2.[ADDRESS_401781] ion6.5.
5.4.1 Caffe ine, Alcohol, and Tobacco
Parti cipants shoul d not sm oke one hour pri or to l ung f unction assessments on clinic visit 
days.
Parti cipants will abstain from ingest ing caffeine -or xanthine -containing products (eg, 
coffee, tea, cola drinks, and chocolate) for 6 hours before and for the duration of each in -
clinic study  visit.
5.4.2 Activity
Parti cipants will abstain from strenuous exercise during Holter ECG collect ion for at least 
[ADDRESS_401782] ion assessments at site.
5.5 Screen Failures
Screen failures are defined as part icipants who consent to participate in the clinical study  but 
are not subsequent ly rando mly assigned to study  intervent ion. A minimal set of screen failure 
inform ation is required to ensure transparent reporting of screen failur e parti cipants to m eet 
the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory  authori ties. Minimal information includes demography , 
screen failure details, eligibilit y criteria, and any  serious AE (SAE).
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay be 
rescreened. Only  a single rescreening is allo wed in the study . Rescreened parti cipants shoul d 
be assigned the same participant number as for th e init ial screening.
In the fo llowing si tuations, the parti cipant m ust be screen failed:
Parti cipants who experi ence m oderate or severe COPD exacerbat ion or respi [INVESTIGATOR_325329]. They may be rescreened but no sooner than [ADDRESS_401783] date of 
hospi [INVESTIGATOR_28689], whatever occurred later
(Excl usion criterion 6 ).
Parti cipants who had SARS -CoV -[ADDRESS_401784] ion (positive nasopharyngeal test) or that 
requi red hospi [INVESTIGATOR_325330] t [ADDRESS_401785] ion, upon approval o f the AZ Study  
Physician (Exclu sion cri terion 7 ).
Rescreening of a participant for any  reason will  be allowed only  upon approval  of the
[COMPANY_008] Study  Physician. A documented approval for rescr eening should be filed in the
Invest igator Study  File.
Clinical Study Protocol -2.[ADDRESS_401786] igational intervent ion(s), m arketed product(s) or 
placebo intended to be administered to or medical device(s) utilized by a study  parti cipant 
according to the study  protocol .
Placebo MDI devices wit h HFA will be provided for training purposes.
6.1 Study Intervention(s) Administered
6.1.1 Investigational Products
Table 4 Investigational Products
Arm  name [CONTACT_325423]/salbutamol
Intervention name [CONTACT_325424]/ 
Glycopyrronium/ 
Formoterol fumarate 
pressurized inhalation 
suspension, HFOBudesonide/ 
Glycopyrronium/ 
Formoterol fumarate 
pressurized inhalation 
suspension, HFAAlbuterol sulfate 
inhalation aerosol 
(US) / Salbutamol 
sulfate inhalation 
aerosol (EU/RoW)
Type Combination product Combination product Combination product
Dose formulation Inhaler Inhaler Inhaler
Unit dose 
strength(s) 
(Delivered dose)160/7.2/4.8 μg per 
actuation160/7.2/4.8 μg per 
actuation90 μg per actuation 
(US) 100 μg per 
actuation (EU/RoW)
Dosage level(s) 2 inhalations BID 2 inhalations BID Rescue : Variable 
(2inhalations as 
needed)
Reversibility : as 
directed for 
reversibility testing at 
Visit 2 
Route of 
administrationOral inhalation Oral inhalation Oral inhalation
Use Experimental Comparator Rescue medication
IMP and NIMP IMP IMP NIMP
Sourcing Provided centrally by [CONTACT_325379], subsidiary, 
or designee
Packaging and 
labelingStudy Intervention will 
be provided in MDI. 
Each MDI will be Study Intervention will 
be provided in MDI. 
Each MDI will be N/A
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 39of 105labeled as required per 
country requirementlabeled as required per 
country requirement
Abbreviations: BGF= budesonide, glycopyrronium, and formoterol fumarate; BID= twice daily (‘ bis in die’ ); 
HFA=hydrofluoroalkane; HFO=hydrofluoroolefin; IMP= Investigational Product; MDI= metered -dose inhaler; 
N/A= Not applicable; NIMP=Non -Investigational Medicinal Product.
The study  intervent ions (BGF MDI HFO and BGF MDI HFA) are each formulated as a 
suspension wit h micronized budesonide, micronized glycopyrronium bro mide, and 
micronized formoterol fumarate cry stals co-suspended with spray -dried porous parti cles in the 
respective propellant (HFO or HFA). The spray -dried porous particles are co mposed of 
distearoylphosphat idylcho line and calcium chloride. Each formulat ion is contained wit hin a 
coated aluminum canister fitted with a metering valve, desiccated flow path collar, and plast ic 
actuator. The canister has an attached dose indicator which indicates how many inhalat ions 
remain. The products are individually  foil overwrapped wi th desiccant and are formulated 
with sufficient suspensio n to ensure delivery  of [ADDRESS_401787] maintenance procedures as described in the IFU.
Dosing instructions and dispensing details will be provided b y [COMPANY_008].
Details o f the batch numbers will be included in the trial master file and the final CSR.
[IP_ADDRESS] HFO excipi[INVESTIGATOR_325331], cost -effect iveness, and 
greater energy  efficiencies. Commo n syno nyms incl ude HFO -1234ze and R -1234ze(E). HFO -
1234ze i s also known as trans -1,3,3,[ADDRESS_401788] IB for more informat ion.
[IP_ADDRESS] HFA excipi[INVESTIGATOR_325332] -134a is a wi dely used propellant used in MDI inhalat ion products. Laboratory  studi es for 
up to 26 weeks (6 months) did not show any  clinically  meaningful differences, compared to 
placebo, in toxi cology or carcinogenic effects. 
The l ack of  adverse findings supports the safet y of this excipi[INVESTIGATOR_840]. HFA -134a is not inert as 
the now redundant chlorofluorocarbons, as it acts as a smooth muscle relaxant‚ partial 
pressure effects in the lungs and inhaled, and has an esthetic effects ( Sellers 2017) .
Refer to the latest IB for more informat ion.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 40of 1056.1.2 Medical Devices
1.The m edical  device consti tuent of  the combination products to be used in this study  
will be an MDI (Approved).
2.Instructions for m edical  device use are provided in the Invest igator Brochure and 
Combinat ion Products section of the Summary  of Medical  Product Characterist ics. 
3.All device const ituent deficiencies (including malfunct ion, use error and inadequate 
labeling) shall be documented and reported by  [CONTACT_325380] (see Sect ion 8.3.11 ) and appropriately managed by [CONTACT_1034].
6.1.3 Active Pharmaceutical Ingredient (API): BGF (PT010) Triple 
Combination Dose
[IP_ADDRESS] Budesonide
Budesonide is a well -established corticosteroid approved as monotherapy  and in combinat ion 
worldwide in both intranasal and orally inhaled formulat ions for different indicat ions, 
including COPD.
[IP_ADDRESS] Glycopyrronium
Glycopy rroni um (the active mo iety of glycopy rronium  bromide, al so referred to as 
glycopy rrolate) i s a LAMA, which exerts its bronchodilatory  effect vi a muscarinic receptors 
located on sm ooth m uscle cells wit hin the trachea and bronchi. Glycopy rronium  is approved 
in many countri es in mult
iple formulat ions f or different indications, including COPD.
[IP_ADDRESS] Formoterol fumarate
Form oterol  fumarate is a potent and select ive LABA and is approved in the US and worldwide 
in combinat ion with budesonide as well as with glycopy rroni um for use in pati ents wi th 
COPD. When inhaled, formoterol fumarate acts locally in the lung as a bronchodilator. 
Form oterol  fumarate stimulates β 2adrenoreceptors in the airways, inducing airway smooth 
muscle rel axation and reducing or preventing bronchoconstrict ion.
Although form oterol  fumara te is classified as a LABA, it has a rapid onset of action similar to 
SABAs. Formoterol fumarate is highly potent, displays high intrinsic act ivity, and can resul t 
in greater than 80% relaxat ion even under induced tone ( Naline et al 2007). Studies in pat ients 
with COPD have dem onstrated that the onset of action with formoterol fumarate is faster than 
with anticholinergic agents or salmeterol and similar to that of SABAs, such as albuterol, and 
that the duration of action is ≥12 hours ( Berger et al 2008 ). Five large, placebo -controlled 
clinical studies o f up to 52 weeks (12 months) in duration in nearly [ADDRESS_401789] ive and well tolerated in patients with COPD 
(Berger et al 2008 )
.
6.2 Preparation/Handling/Storage/Accountability
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 41of 105The Investigator or designee must confirm appropriate temperature condit ions have been 
maintained during transit for all study  intervent ion received and any discrepancies are 
reported and resolved b efore use of the study  intervent ion.
Only participants enro lled in the study  may receive study  intervent ion and only 
authori zed si te staff may  supply  or administer study  intervent ion. All study  intervent ion 
must be stored in a secure, environmentally contr olled, and mo nitored (m anual  or 
autom ated) area in accordance wit h the l abeled storage conditions with access limited to 
the Invest igator and authorized site staff.
The Investigator, inst itution, or the head of the medical inst itution (where applicable) is
responsible for study  interventi on accountabilit y, reconciliat ion, and record maintenance 
(ie, recei pt, reconciliat ion, and final disposit ion records).
Further gui dance and information for the final disposit ion of unused study  interventi ons 
are provided i n the IP handling instruction.
6.3 Measures to Minimize Bias: Randomization and Blinding
All participants in this internat ional multi-center study  will be centrally assigned to 
rando mized study intervent ion using an Interactive Response Technology /Randomizat ion and 
Trial Supply Management (IRT/RTSM). Before the study  is init iated, user guides, the log- in 
inform ation, and directions of the IRT will be provided to each study  site. Randomizat ion will 
be stratified by  [CONTACT_11338] (Americas, Europe) and COPD disease sev erity (percent predi cted 
FEV1 ≥ 50%, percent predicted FEV1 < 50%). The IRT/RTSM will provide to the 
Invest igator(s) or pharmacists the kit ident ificat ion number to be allocated to the participant at 
the dispensing visit. Routines for this will be describe d in the IRT/RTSM user manual that 
will be provided to each center.
This study  is doubl e-blinded with regard to treatment; ie, the Sponsor, the Invest igator, all 
clinical staff invo lved in the clinical study , the participants, and the Study  Moni tor will re main 
blinded, unless safet y concerns or a regulatory  requi rement necessitate unblinding.
The Supply  Chain Study  Manager, who i s unblinded to manage drug supply effect ively and 
perform  transact ions that take effect immediately, may have access to the RTSM s ystem. 
Neither the Supply  Chain Study  Manager nor the IRT Delivery  Team  Lead will be granted 
access to the EDC system.
The rando mizat ion code should not be broken except in medical emergencies when the 
appropriate management of the participant requires kno wledge of the treatment 
rando mizat ion.
[COMPANY_008] retains the right to break the code for SAEs that are unexpected and are 
suspected to be causally  related to an invest igational product and that potentially  require 
Clinical Study Protoc ol-2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 42of 105expedited reporting to regulatory  author ities. A copy  of the report, i dentifying the participant’s 
intervent ion assignment, may be sent to Invest igators in accordance with local regulat ions 
and/or Sponsor policy . Randomizat ion codes will not be broken for the planned analyses of 
data until all d ecisio ns on the evaluabilit y of the data from  each individual participant have 
been made and documented.
The IRT will be programmed with blind -breaking instructions. In case of an emergency, in 
which the knowledge of the specific blinded study  intervent ionwill affect the immediate 
management of the participant’s condit ion (eg, antidote available), the Invest igator has the 
sole responsibilit y for determining if unblinding of a participant’s intervent ion assignment is 
warranted. The participant’s safet y mustalways be the first consideration in making such a 
determinat ion. If a participant’s intervent ion assignment is unblinded, the Sponsor must be 
notified wit hin [ADDRESS_401790] igator regarding whether to continue 
or discontinue the participant.
Returned study  intervent ion shoul d not be re -dispensed to the participants.
6.4 Study Intervention Compliance
Study  parti cipants will be trained by [CONTACT_325381]-administer the study  treatm ent. 
When participants are dosed at the site, they  will self -administer and inhale study  intervent ion 
under medical supervisio n from the Inve stigator or desi gnee. 
The date, and time of dose administered during on -site visi t will be recorded in the source 
docum ents and in the electronic Case Report Form (eCRF). 
Com pliance wi th at hom e study  intervent ion self -administrati on will be assessed at each on -
site visi t. 
Authori zed si te staff representative will assess study  intervent ion compliance by [CONTACT_325382] (number of remaining doses) on returned MDI devices. The puff indicator 
reading should be documented in the source documents and in the eCRF to allow to monitor 
study  interventi on com pliance and for reconciliat ion.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 43of 105The number of MDI devices dispensed and used/returned will be recorded at each on -site 
visit.
Study  intervent ion start date/time and stop date/time will also be recorded in the eCRF. 
6.5 Concomitant Therapy
6.5.1 Perm itted During the Course of the Study
Parti cipant’s m ay cont inue current maintenance treatment for COPD, during the 
screening/run -in period, Visit 1 to Visi t 3.
SABA -Sponsor provided to be used as needed during study  conduct from  Visi t [ADDRESS_401791] of prohibited medications is provided in Table 5.
Table 5 Prohibited medications
COPD Medications -Minimum Required Washout Periods Prior to Lung Function Assessment at Visit 2 
to Visit 3
SABA 6 hoursa
SAMA 6 hours
LABA (mono and in any combination) 12 hours (24 hours for once daily medications)
LAMA (mono and in any combination) 12 hours (24 hours for once daily medications)
COPD Medications -Minimum Required Washout Periods Prior to Study Intervention Administration at 
Visit 4 to Visit 9
SABA 6 hoursa
Study Medication 12 hours
COPD medications prohibited prior Visit 1 and throughout the study
Combinations of SAMA/SABA 2 weeks
Oral beta -agonists 2 weeks
Xanthine derivatives 2 weeks
Maintenance/prophylactic treatment with oral, 
systemic, or depot corticosteroidsb26 weeks (6 months)
Maintenance/prophylactic treatment with antibioticsc 26 weeks (6 months)
Leukotriene antagonists/modifiers (eg, zafirlukast, 
montelukast, Zileuton®)7 day s
Prohibited Non -COPD and Non -Respi[INVESTIGATOR_325333] 1 and throughout the study
Intranasal ipratropi[INVESTIGATOR_1893] 7 day s
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 44of 105Any drug with potential to significantly prolong the 
QT intervale 14 days or 5 half -lives, whichever is longer
Other investigation drugs 30 days or 5 half -lives, whichever is longer
Nonselective beta -blocking agents (except 
carvedilol)7 day s
Monoamine oxidase inhibitors 14 days
Monoclonal antibodiesf 30 days or 5 half -lives, whichever is longer
Systemic treatment with strong CYP3A4 -inhibitors 
(eg, ketoconazole, itraconazole, ritonavir)30 days
Systemic anticholinergicsg 7 day s
Maintenance/prophylactic treatment with oral, 
systemic, or depot corticosteroids12 months
Herbal remedies for the treatment of allergic, 
inflammatory, or respi[INVESTIGATOR_325334] (eg, Chinese 
complementary and alternative bronchodilatory 
medications)14 days
Live attenuated vaccines 30 days
COVID -19 vaccines (any dose from regimen) 7 day s prior to randomization and any spi[INVESTIGATOR_1892].
a. All SABA use will be stopped at Visit 1 and participants will be switched to Sponsor -provided albuterol/salbutamol for 
use as needed throughout the study.
b. Short -term, occasional use of corticosteroids for the treatment of a COPD exacerbation is allowed.
c. Short -term, occasional use of anti biotics for infections or the treatment of a COPD exacerbation is allowed. 
d. Any medications that, in the opi[INVESTIGATOR_689], would impact the safety of the study or the outcome of the 
study  is prohibited. 
e. Participants who are on medication that h ave the potential to prolong the QTc interval may be enrolled provided the 
dose has remained stable for at least 12 weeks (3 months) prior to Visit 1, the participant meets none of the ECG 
exclusion criteria and if, in the opi[INVESTIGATOR_689], ther e are no safety concerns for the participant in the study. 
Initiations of medications with potential to significantly prolong the QT interval is prohibited throughout the Screening 
and Randomized Treatment Periods. Note: Short courses ( ≤ 4 weeks) of antibi otics with the potential to prolong the QT 
interval (eg, azithromycin, clarithromycin) are permitted. 
f. Investigators should contact [CONTACT_325383] a case -by-case basis (a monoclon al antibody for another indication, such as osteoporosis, may be allowed after 
consultation with the Study Physician).
g. If systemic anticholinergics are used for the treatment of overactive bladder and the treatment has been constant for at 
least 1 month, t hey are allowed. 
6.5.3 Restricted Medications
Medicat ions only  allowed wi th defined stable dosing period prior to Visit 1 are listed in Table 
6.
 
Table 6 Restricted medications
Medications Only Allowed with Defined Stable Dosing Period Prior to Visit 1
Selective serotonin reuptake inhibitors/serotonin 
and no repi[INVESTIGATOR_5608]4 weeks
Tricyclic antidepressants 6 weeks
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 45of 105Medications Only Allowed with Defined Stable Dosing Period Prior to Visit 1
Antipsychotics 6 weeks
Anticonvulsants 52 weeks for seizure disordersa
12 weeks for other conditions
Non-sedating long -and short -acting 
antihistamines7 day s
Intranasal corticosteroids 7 day s
Intranasal antihistamines or combination 
products of intranasal 
antihistamines/corticosteroids7 day s
Roflumilast [ADDRESS_401792] be free of seizures for 1 year prior to Visit 1.
6.5.4 Rescue Medicine
[IP_ADDRESS] SABA
Albuterol  sulfate (US)/Salbutamo l sulfate (EU/RoW) inhalat ion aerosol; (Albuterol 90 µg per 
actuation/Salbu tamol 100 µg actuation). 
Two inhalat ions as needed for rescue medicat ion. As di rected for eligibilit y testing.
6.6 Intervention After the End of the Study
Parti cipants who com plete Week 52/Visit 9/Withdrawal Visit (or Week 12/Visit 6/Wit hdrawal 
Visit for those not entering the extensio n study ) shoul d be given locally  available standard -of-
care treatm ent at the discretion of the Invest igator.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 46of 1057 DISCONTINUATION OF S TUDY INTERVENTION AN D 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL
7.1 Discontinuation of Study Interventi on
It may be necessary  for a parti cipant to perm anent ly discont inue study  intervent ion. If study  
intervent ion is permanent ly discont inued, the participant should be encouraged to attend the 
on-site Wi thdrawal  Visi t (not l ater than wit hin [ADDRESS_401793] d ose) and subsequent fo llow-
up telephone contact [INVESTIGATOR_874] [ADDRESS_401794] be 
discontinued:
Development of exclusio n criteria or other safet y reasons as judged by [CONTACT_325384];
Pregnancy or breastfeeding;
Paradoxi cal bronchospasm.
If a participant experiences the change of c oncern listed below, a repeat assessment should be 
obtained, and if confirmed, the study  intervent ion must be discont inued:
Calculated QTcF of either > 500 msec OR a ≥ 60 msec change from the value obtained at 
Visit 1;
Decrease in eGFR to a value ≤ 30 mL/m inute using CKD -EPI f ormula for partici pants [ADDRESS_401795] igator. 
Parti cipant m ay be discont inued from study intervent ion in the fo llowing si tuations:
Parti cipant decisio n. The participant is at any t ime free to di scont inue study  intervent ion, 
without prej udice to further treatment;
An adverse event considered to jeopardize the safety  of a parti cipant parti cipat ing in the 
study;
Severe nonco mpliance with the CSP;
Lost to follow up;
Development of any study  specific cri teria for discontinuat ion;
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 47of 105Any malignancy , except partici pants who devel op basal  cell carcino ma or l ocalized 
squamous cell carcino ma of the skin, provided that the malignancy has been excised and 
deter mined to have clear margins;
Other reasons.
See the SoA Table 1for data to be collected at the Wit hdrawal (post study  interventi on 
discontinuat ion) and fo llow-up visi ts and f or any  further eval uations that need to be 
completed.
If a participant discont inues study  intervent ion due to a study  specific discont inuat ion 
criterion, this shoul d always be recorded as ‘Development of Study  Specific Discontinuation 
Criteria’ on the Discontinuat ion of Invest igation Product form in the eCRF.
7.1.1 Temporary Discontinuation
The Sponsor reserves the right to temporarily suspend or permanent ly terminate this study  or a 
component of the study  at any  time. The reasons for temporarily suspendi ng the study  may 
include, but are not limited, to any  death, seri ous adverse events (SAE), or other safet y finding 
assessed as related to study  interventi on that in the opi[INVESTIGATOR_3078] n of the Sponsor may preclude 
further study  intervent ion.
7.2 Participant Withdrawal from the Study
A participant may withdra w from the study  at any  time at hi s/her own request, or at the 
request of their legally authorized representative, or may be withdrawn at any t ime at the 
discreti on of  the Investi gator f or safet y, behavioral, compliance, or administrative reasons. 
This is 
expected to be uncommo n.
A participant and/or their legally authorized representative who considers wit hdrawing fro m 
the study  must be inform ed by  [CONTACT_325385]-up opti ons (eg, 
telephone contact, a contact [CONTACT_4490] a relative or treati ng physician, or informat ion from medical 
records).
If the participant and/or their legally authorized representative withdraws consent for 
disclosure of future informat ion, the Sponsor may retain and cont inue to use any data 
collected before such a withdr awal of consent.
If a participant and/or their legally authorized representative withdraws from the study , it 
shoul d be confirmed if the participant and/or their legally authorized representative st ill agrees 
for exist ing samples to be used in line with th e original consent. If he/she and/or their legally  
authori zed representative requests withdrawal o f consent for use of samples, destruction of 
any samples taken and not tested should be carried out in line wit h what was stated in the 
informed consent and l ocal regul ation. The Invest igator must document the decisio n on use of 
exist ing samples in the site study  records and inform the Glo bal Study  Team .
Clinical Study Protocol -2.[ADDRESS_401796] be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact [CONTACT_2299]/legally authorized repres entative and 
reschedule the missed visit as soon as possible and counsel the participant/legally 
authori zed representative on the importance of maintaining the assigned visit schedule 
and ascertain whether or not the participant/legally authorized represen tative wishes to 
and/or shoul d continue in the study .
Before a participant is deemed lost to fo llow-up, the Invest igator or designee must make 
every effort to regain contact [CONTACT_6635]/legally authorized representative (where 
possible, 3 telephon e calls and, if necessary , a certified l etter to the parti cipant’s/legally 
authori zed representative's last known mailing address or local equivalent methods). 
These contact [CONTACT_13140]’s medical record.
Shoul d the part icipant continue to be unreachable, he/she will be considered to have 
withdrawn from  the study .
Discontinuati on of  specific sites or of the study  as a who le are handled as part of Appendix A.
8 STUDY ASSESSMENTS AN D PROCEDURES
Study  procedures and their timing are summarized in the SoA 
(Table 1)
. Protocol waivers or
exempt ions are not allowed.
Immediate safet y concerns should be discussed wit h the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue study  
intervent ion.
Adherence to the study  design requi remen ts, including those specified in the SoA, is essent ial 
and required for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potential 
participants m eet all eligibilit y criteria. The Invest igator will maint ain a screening log to 
record details o f all participants screened and to confirm eligibilit y or record reasons for 
screening failure, as applicable.
Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signi ng of  the ICF m ay be utilized for screening or baseline 
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 49of 105purposes provided the procedures met the protocol -specified criteria and were performed 
within the t ime frame defined in the SoA ( Table 1).
8.[ADDRESS_401797] (CAT)
The CAT i s an 8 -item patient reported outcom e (PRO) developed to measure the impact of 
COPD on health status ( Jones 2009 )
. The instrument uses semantic different ial six-point 
response scales which are defined by [CONTACT_244964]. 
Content includes items related to cough, phl egm, chest ti ghtness, breathlessness going up 
hills/stairs, activit y limitation at home, confidence leaving ho me, sleep, and energy. 
A CAT total score is the sum of item responses. Scores range from [ADDRESS_401798] on healt h status. The CAT will be co mpleted by  [CONTACT_325386] 1, 6, 9 and Wit hdrawal Visit as specified in the SoA ( Table 1) . If the subject is not 
able to visit the site, CAT may be co mpleted by  [CONTACT_189531] e/alternat ive location. Refer 
to Appendix Ffor details.
8.2 Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA (see
 Table 1) .
8.2.1 Physical Exa minations
A co mplete physical examinat ion and a brief physical examinat ion will be perf ormed at tim es 
as specified in the SoA (see Table 1
). A com plete physical  examinat ion will include an 
assessment of the fo llowing: general  appearance, skin, head, eyes , ears, nose, throat, neck 
(including thyroid), lymph nodes, chest, heart, abdomen, extremit ies, and nervous system. A 
brief physical examinat ion will include the evaluatio n of fo llowing: general  appearance, 
respi [INVESTIGATOR_696] , cardi ovascular and abdom en.
Height and weight will be measure at Visit 1 (Screening).
8.2.[ADDRESS_401799] 5 minutes, 
by [CONTACT_244967] (how many times the chest rises) for 1 minute.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 50of 105Body  temperature will be recorded in Celsius in accordance with local standards.
Vital signs will  be perform ed at times as specified in the SoA (see Table 1) .
[IP_ADDRESS] Weight and height
Weight and height will be measured in accordance with the SoA in Table [ADDRESS_401800]’s 
weight will be recorded in kilograms, and height will be recorded in cent imeters. Weight and 
height measurements will be performed in light clothing a nd wit h shoes off.
8.2.3 Smoking Status
Smoking status will be assessed at every  visit starting from  enro llment (Visit 1) unt il their 
End-of-Treatm ent or Wi thdrawal  Visi t by [CONTACT_244966]’s response to a single yes/no 
question fro m study  personnel: ‘Wha t is y our sm oking status as of today , do y ou currently  
smoke?’ Sm oking status changes during Visit [ADDRESS_401801] at Visits 1, 4, 5, 
9/Final Visit and Wit hdrawal Visit as specified in the SoA ( Table 1)
. The Invest igator or 
authori zed delegate will be responsible for the overall interpretation and determinat ion of 
clinical significance of any potential ECG findings. In case of discrepancy between the 
Invest igator’s interpretati on and that provided by  [CONTACT_325387] m achine (if applicable), the 
Invest igator’s interpretation will take precedence and should be noted on the printout and 
recorded in the eCRF. A copy  of the ECG will be produced, qualit y checked by  [CONTACT_325388] -evaluat ion. ECG to be collected prior to 
any blood draws, spi[INVESTIGATOR_038] , and IP administration. 
The calculated QTcF intervals will be reviewed and checked for gross inaccuracies by [CONTACT_325389]. 
Parti cipants who experi ence a change of QTcF intervals from their Visit [ADDRESS_401802] ion
 7.1.
A digital 12 -lead Holter ECG will be performed at Visit 3 (rando mizat ion)/Visit [ADDRESS_401803] ions.
Continuous Digital 12- lead Ho lter ECG will be con nected the day  prior to Visit 3 
(randomization)/Visit 6 to allow for 24 hours ECG recordings and ECG extractions at the 
following t ime points: 60 min pre -dose and 20 min, 60 min & [ADDRESS_401804] dose (see
 Table 2) . 
Clinical Study Protocol -2.[ADDRESS_401805] dose ECG extractions should be completed 
prior to the spi [INVESTIGATOR_325335]. 
Holter hook up procedure should be completed/ ECG recordings are to be init iated 1 day  prior 
to scheduled Visit 3 and 6 at approximately the same time wit hin the fo llowing time window 
13:00 (±2 hr) for both visits. Holter Monitor will be removed from the study  parti cipant at 
Visit [ADDRESS_401806] all 12 -lead safety  
ECGs, 24 -hour Holter recordings, and related digit al 12-lead ECG extractions from Ho lter 
recordings. Twent y
-four-hour Holter recordings (collected at Visit 3 and Visit 6) will be 
transferred to an external vendor, where qualified personnel will extract digital 12 -lead ECGs 
from the recordings (to support t imepo ints specified in Table 2)  and perform centralized 
assessment of provided data to assure data qualit y and consistency in data interpretation.
The sa me centralized assessment and data interpretation will be applied to all 12 -lead safet y 
ECGs (collected at Visits 1, 4, 5, 9/Final Visit, and Withdrawal Visit), as related ECG 
recordings in digital/electronic format will be shared with the external vendor. Results of 
related assessments will be shared with Invest igators. In case of significant abnormalit ies 
ident ified in co llected ECG/Holter data, Invest igators will be contact[CONTACT_325390].
More details wi ll be present in manual covering details for 12- lead ECG/Hol ter m onitoring.
8.2.5 Spi[INVESTIGATOR_325336]1, FVC, FEV1/FVC ratio as 
defined in American Thoracic Society  (ATS)/European Respi[INVESTIGATOR_21584] y (ERS) gui delines 
will be performed in accordance with ATS/ERS acceptabilit y and repeatabilit y criteria will be 
assessed using a spi[INVESTIGATOR_325337] m eets or exceeds minimum performance reco mmendat ions. 
Spi[INVESTIGATOR_325338] m eet both acceptabilit y and repeatabilit y criteria ac cording to ATS/ERS 
2019 recommendations. Calculated predicted spi[INVESTIGATOR_325339] (GLI) equations ( Quanjer 2012
).
Allstudy  staff responsible for performing spi[INVESTIGATOR_325340] y to perf orm technically  accepta ble spi[INVESTIGATOR_325341] (ATS criteria) prior to performing any spi[INVESTIGATOR_325342] .
Clinical Study Protocol -2.[ADDRESS_401807] 
time for morning COPD maintenance treatment administration; at Visit 2, spi[INVESTIGATOR_325343]  [ADDRESS_401808] -dose.
At Visits 3 to 9 (including any needed Unscheduled Visits, if neede d), spi [INVESTIGATOR_325344] [ADDRESS_401809] dosing of study  drug at 5, 15, 
30 and 60 min (see Table 2) .
During withdrawal (WD) visit, trough spi[INVESTIGATOR_325345]  [ADDRESS_401810] COPD maintenance treatment.
The procedure for testing reversibilit y to albuterol  at Vi sit 2 isas fo llows:
1.Confirm that COPD medication washout criterion was met, including salbutamo l or 
albuterol  was wi thheld for at l east [ADDRESS_401811] FEV1 effort obtained at 30 minutes (or up to 
60 minutes, if repeated) post -bronchodilator fo llowing administration of albuterol.
8.2.6 Clinical Safety Laboratory Assessments
The clinical chemistry  and hematol ogy will be perform ed at a central laboratory , except for 
urine human chorionic gonadotropin (hCG) test which will be performed at study site 
(dipstick). All protocol -requi red laboratory  assessments must be conducted in accordance wit h 
the laboratory  manual .
Clinical Study P rotocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 53of 105All clinical laboratory  tests will be obtained at Visit 1 (Screening) and at Visit 3 
(Rando mizat ion), Vi sit 6 (Week 12), and Vi sit 9 (Week 52), End -of-treatm ent/Wi thdrawal  
Visit, and any Unscheduled Visit (if needed, at the discretion of the Investigator), see SoA 
Table 1.
The Investigator sho uld assess the available results regarding clinically  relevant abnorm alities. 
The l aboratory  resul ts shoul d be signed and dated and retained at center as source data for 
laboratory  variables. The laboratory  variables listed in Table 7will be measured.
For informat ion on how AEs based on laboratory  tests shoul d be recorded and reported, see 
Secti on 8.3.5 .
If an emergent event results in centralized laboratory  testi ng of samples not being available, 
the Sponsor may decide to use local laboratories. 
Table 7 Clinical Laboratory Tests
Screening (and as applicable during 12 -week and 52 -week Treatment periods [see Table 1])
Hematology/Hemostasis (whole blood) Clinical Chemistry (serum or plasma)
B-Hemoglobin (Hb) Creatinine
B-Leukocyte count Bilirubin, total
B-Leukocyte differential count (absolute count) Alkaline phosphatase (ALP)
B-Platelet countAspartate transaminase (AST)
Alanine transaminase (ALT)
S-β-hCG (Pregnancy test) at Visit [ADDRESS_401812] is only required for eligibility check. FSH is tested at Visit 1 for women <50 years of age with 
amenorrhea for 12 months without an alternative medical cause.
b. eGFR estimated by [CONTACT_91019] -EPI [INVESTIGATOR_14420] ( Levey 2009 ) for participants [ADDRESS_401813] 
randomization troponin should be checked according to the Investigator’s dec ision and only when clinically 
indicated for potential Adverse Events diagnosis/reporting.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 54of 1058.2.6.1 Hematology
Hem oglobin, whi te blood cell count wi th differential, platelet count will be measured at 
Visit1 (Screening) and at Visit 3 (Randomization), Visit 6 (Wee k 12) and Visit 9 (Week 52) 
and the End- of-treatm ent/Wi thdrawal Visit.
[IP_ADDRESS] Clinical chemistry
Creatinine, total bilirubin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), glucose, potassium and sodi um, will be measured at Vi sit 1 
(Screening) and at Visit 3 (Rando mizat ion), Vi sit 6 (Week 12) and Vi sit 9 (Week 52) and the 
End-of-treatm ent/Wi thdrawal Visit.
[IP_ADDRESS] Pregnancy test
Serum  pregnancy test will be performed at Visit 1 (Screening) for women o f childbearing 
potenti al. 
The fo llowing tests are applicable to female subjects only  and will  be conducted in accordance 
with the schedule provided in SoA Table 1.
Serum ß-human chorionic gonadotropin (ß -hCG) –the test done at enrollment (Visit 1) 
only, for WOCBP (analyzed at central laboratory ).
FSH –the test done at enrollment (Visit 1) only, fo r female subjects to confirm 
postm enopausal status in women <[ADDRESS_401814] been amenorrhoeic for 
>
12months (analyzed at central laboratory ).
Urine β -hCG –the test will be performed at the study  site for WOCBP at each visit 
before IP administration using a dipst ick. Posit ive urine β -hCG test result must be 
confirmed wit h serum β -hCG analyzed at central laboratory . 
8.[ADDRESS_401815] ion.
The definit ions of an AE or SAE can be found in Appendix B.
The definit ions of medical device -related safet y events, (Medi cal device (SAE), adverse 
device effects [ADEs] and SADEs), can be found i n
 Appendix F. Medical  Device deficiencies 
are covered in Sect ion
 8.3.11 .
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 55of 105Adverse events will be reported by  [CONTACT_17071] (or, when appropri ate, by  a caregiver, 
surrogate, or the participant's legally authorized representative). 
The Investigator and any designe es are responsible for detecting, document ing, and recording 
events that meet the definit ion of an AE.
8.3.1 TimePeriod and Frequency for Collecting AE and SAE Information
Adverse events will be collected from rando mizat ion, Visit 3 throughout the treatment per iod 
and including the fo llow-up peri od/last contact. 
Throughout the study  AEs will be captured every  [ADDRESS_401816] and/or site 
visits (tel ephone: Weeks 2, 6, 10, 14, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, 38, 42, 44, 46, 48, 
50, and 54; i n-person site visits: Weeks 0, 4, 8, 12, 26, 40, and 52, as well as at any  applicable 
Unscheduled or Withdrawal visit s; see SoA in Table 1) .
All SAEs will be recorded from the time of signing of the ICF, throughout the treatment 
period and including the fo llow-up peri od, up to the final visit.
All AEOSIs will be recorded from the time of the first dose, throughout the treatment period 
and including the fo llow
-up peri od, up to the final visit.
If the Investigator becomes aware of an SAE with a suspected causal relat ionship to the 
investigat ional medicinal product that occurs after the end of the clinical study  in a parti cipant 
treated by  [CONTACT_198671], the Invest igator shal l, without undue del ay, report the SAE to the 
Sponsor.
8.3.2 Follow- up of AEs and SAEs
Any AEs that are unresolved at the participant’s last AE assessment in the study  are 
followed-up by  [CONTACT_325391], but without further 
recording in the eCRF. [COMPANY_008] retains the right to request additional informat ion for any  
participant wi th ongoing AE(s)/SAE(s) at the end of the study , if judged necessary .
Adverse event variables
The fo llowing variables will be collected for each AE :
AE (verbat im)
The date when the AE started and stopped
Maximum intensit y
Whether the AE is serious or not
Invest igator causalit y rating against the Investigat ional Product(s) (y es or no)
Action taken with regard to Investigat ional Product(s)
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 56of 105AE caused participant’s wi thdrawal  from study (yes or no)
Outcom e
In addit ion, the fo llowing vari ables will be collected for SAEs:
Date AE m et cri teria for SAE
Date Invest igator became aware of SAE
AE is seri ous due to
Date of Hospi[INVESTIGATOR_059]
Date of discharge
Proba ble cause of death
Date of death
Autopsy  performed
Causalit y assessment in relat ion to study  procedure(s)
Causalit y assessment to other medicat ion.
Maximum intensit ies will be reported for each AE. Maximum intensit y refers to the complete 
course of the AE. The participants will be asked to assess the maximum intensit y of the 
reported AEs according to the fo llowing scale:
Mild (awareness of sign or symptoms, but easily tolerated)
Moderate (di scomfort sufficient to cause interference with normal act ivities)
Severe (incapacitat ing, with inabilit y to perform  norm al activities).
8.3.3 Causality Collection
The Investigator shoul d assess causal relat ionship between study  interventi on and each AE, 
andanswer ‘yes’ or ‘no’ to the question ‘Do y ou consi der that there is a r easonable possibilit y 
that the event may have been caused by  [CONTACT_33159]?’
For SAEs, causal relat ionship should also be assessed for other medicat ion and study  
procedures. Note that for SAEs that could be associated with any study  procedure the causal 
relationship is implied as ‘yes’.
A guide to the interpretation of the causalit y quest ion is found in Appendix Bto thi s CSP.
8.3.4 Adverse Events Based on Signs and Symptoms
All AEs spontaneously reported by  [CONTACT_41413] l egally authori zed representative or 
reported in response to the open question fro m the study  site staff: ‘Have y ou had any  heal th 
probl ems since the previous visit/y ou were l ast asked?’ , or reveal ed by  [CONTACT_325392]. When co llecting AEs, the recording of diagnoses is 
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 57of 105preferred (when possible) to recording a list of signs and symptoms. However, if a diagnosis is 
known and there are other signs or symptoms that are not generally part of the diagnosis, the 
diagnosis and each sign or symptom will be recorded separately.
8.3.5 Adverse Events Based on Examinations and Tests
The results from the CSP -mandated laboratory  tests and vi tal signs will be summarized in the 
Clinical Study  Report (CSR). 
Deteri oration as com pared to baseline in protocol -mandated vital signs shoul d therefore only 
be reported as AE s if they fulfill any o f the SAE criteria, are the reason for discont inuat ion of 
treatm ent wi th the invest igational product or are considered to be clinically relevant as judged 
by [CONTACT_24342] (which may include but not limited to consideration as to whether 
treatm ent or non -planned visits were required or other action was taken with the study  
intervent ion, eg, dose adjust ment or drug interruption).
If deteri oration in a laboratory  value/vi tal sign i s associ ated wi th clinical signs and symptoms, 
the sign or symptom will be reported as an AE and the associated laboratory result/vital sign 
will be considered as addit ional informat ion. Wherever possible the reporting Invest igator 
uses the clinical, rather than the laboratory  term  (eg, anemia versus low he moglobin value). In 
the absence of clinical signs or symptoms, clinically relevant deteriorations in non -mandated 
param eters shoul d be reported as AE(s).
All 12 -lead ECG abnormal findings and digital 12 -lead Ho lter ECG abnormal findings 
obtained wit hin the study  will be summarized in the CSR; therefore, they  shoul d not by  
[CONTACT_325393] t be reported individually  as AEs. Abnorm al findings fro m 12-lead ECGs or from 
di
gital 12-lead Ho lter ECGs should only be reported as AEs if they fulfill any o f the SAE 
criteria, are the reason for discont inuat ion of treatment with the invest igational product, or are 
considered to be clinically relevant as judged by [CONTACT_24342] (which may include but is 
not limited to consideration as to whether treatment or non -planned visits we re requi red or 
other action was taken with the study  intervent ion, eg, drug interruption).
Any new or aggravated clinically relevant abnormal medical finding at a physical examinat ion 
as com pared wi th the baseline assessment will be reported as an AE.
8.3.[ADDRESS_401817]
The AEOSIs in this study  are respi [INVESTIGATOR_325319], cough, dyspnea, 
wheezing, paradoxical bronchospasm, bronchospasm, and COPD exacerbat ions.
For handling of AEOSI that are also symptoms of Disease under Study  (DUS) pl ease refer to 
Secti on 8.3.7 .
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C [ZIP_CODE]
CONFIDENTIAL AND PROPRIETARY 58of 105If any o f the AEOSI are reported the participants will be asked about time relatedness to 
inhalat ion.
[IP_ADDRESS] Paradoxical bronchospasm
Paradoxi cal bronchospasm is defined as a reduction in FEV1 of >15% from baseline (ie, the 
FEV1 value obtained within 30 minutes prior to study  intervent ion administration on that 
same day ) that occurs shortly after dosing with associated symptoms o f wheez ing, shortness 
of breath, or cough. A drop in FEV1 >15% fro m baseline with associated symptoms should be 
reported as an AE of paradoxical bronchospasm. 
Moni toring for paradoxi cal bronchospasm will occur at each in -clinic visit by [CONTACT_15209][INVESTIGATOR_325312] [ADDRESS_401818] -dose. If FEV1 drops >15% fro m baseline, m easurements 
shoul d be repeated until FEV1 values have normalized. 
Moni toring of FEV1 will also be done at [ADDRESS_401819] -dose 
recordings included in the paradoxical bronchospasm definit ion.
[IP_ADDRESS] Level of COPD severity by [CONTACT_325394] -bronchodilator FEV1 % predicted.
[IP_ADDRESS] COPD e xacerbation assessment
Assessment of COPD exacerbat ion
For the purpose of this CSP, a moderate or severe COPD exacerbat ion will be defined as a 
worsening in the participant’s usual COPD symptoms that is beyo nd normal day -to-day 
variat ion, is acute in onset , lasts 2 or m ore day s (or less if the worsening is so rapid and 
profound that the treating physician judges that intensificat ion of treatm ent cannot be 
delayed), m ay warrant a change in regular medicatio n, and leads to any  of the f ollowing:
Use of systemi c corti costeroi ds for at l east 3 day s; a single depot injectable dose of 
corticosteroi ds will  be considered equivalent to a 3 -day course of systemic corticosteroids
Use of antibiot ics to treat COPD exacerbat ion for at least 3 days 
An inpatient hospi[INVESTIGATOR_325346] (defined as an inpat ient admission ≥ 24 hours 
in the hospi[INVESTIGATOR_307], an observat ion area, the em ergency department, or other equivalent 
healt hcare facilit y depending on the country  and heal thcare system )
Admissio n in emergency department or emer gency room  due to COPD for < 24 hours 
requi ring intensive treatment; add per study  requi rement. The list of intensive treatment 
will be included in the eCRF instruction, please refer to the standard
Results in death. 
Clinical Study Protocol -2.[ADDRESS_401820] should be obt ained for exacerbations evaluated and treated at non -study  sites (eg, by  
[CONTACT_325395]/hospi[INVESTIGATOR_307]) and details entered into the 
eCRF exacerbat ion module in a timely fashio n. Changes in conco mitant m edicati on due to an 
exacerbati on must be recorded i n the appropriate eCRF.
Severit y of COPD exacerbations
A COPD exacerbat ion will be considered moderate if it requires treatment with systemic 
corticosteroi ds and/or antibiot ics for at least 3 day s, or resulted in emergency  room  visit < 24h 
requi ring intensive treatment; and does not result in hospi[INVESTIGATOR_325347].
A COPD exacerbat ion will be considered severe if it results in hospi[INVESTIGATOR_3094] (defined as an 
inpat ient admissio n ≥ 24h in the hospi[INVESTIGATOR_307], an observat ion area, the em ergency  depart ment, or 
other equivalent healt hcare facilit y depending on the country  and heal thcare system ) or death 
due to COPD. 
Symptom s reporting
Parti cipant will  be encouraged to contact [CONTACT_143292]/or their primary  care physician in 
case of CO PD symptom s worsening. The participant will be asked to inform the Invest igator 
of any COPD -related events treated outside o f the study  site. For COPD symptoms reporti ng, 
see DUS (Section 8.3.7 ).
Durati on of  COPD exacerbat ion
The start and stop of a moderate or severe exacerbation is defined as:
The start date of systemic corticosteroids or antibiotic treatment or hospi[INVESTIGATOR_063], 
whichever occurs earlier, and th e stop date is defined as the last day  of systemic 
corticosteroi ds or antibiot ic treatment or hospi[INVESTIGATOR_2345], whichever occurs later. 
A single depot injectable dose of corticosteroids will be considered equivalent to a 3 -day 
course of systemic cortico steroi ds. The corresponding stop date for this treatment will 
consequent ly be determined as the date of administration plus 2 days.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 60of 105If multiple treatm ents are prescribed for the same exacerbat ion, the earliest start date and 
the latest stop date will be us ed.
For a severe COPD exacerbat ion with no documented corticosteroid or antibiot ics treatment, 
hospi [INVESTIGATOR_325348]/discharge dates, or emergency visit date will be used as start/stop 
dates.
Parti cipants will be queri ed at Visi t 1, Visi t 2 (as applic able), and Visit [ADDRESS_401821] experienced a COPD exacerbat ion, defined as an acute event characterized by a 
worsening of the participant’s respi[INVESTIGATOR_325349]-to-day 
variat ions and leads to a change in COPD medicat ions. In addition, if the Study  Physician 
responds to calls fro m the parti cipant or elevated symptoms reported by  [CONTACT_2299], they  
may determine that the participant is experiencing an exacerbat ion. 
8.3.[ADDRESS_401822] result of COPD. 
Events which are unequivocally due to DUS should not be reported as an AE during the study 
unless:
they meet SAE cri teria 
there is a COPD worsening that meets the protocol definit ion for COPD exacerba tion 
the sign or symptom  are new and/or different from the participants COPD 
history /baseline regardless of serious criteria.
8.3.[ADDRESS_401823], or to the study  procedure(s). All SAEs will be recorded in the eCRF.
If any SAE occurs in the course of the study , investi gators or other site personnel will inform 
the appropriate [COMPANY_008] representatives within [ADDRESS_401824] igators or other site personnel will inform 
[COMPANY_008] representatives of any  follow-up informat ion on a previously  reported SAE 
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 61of 105within 1 calendar day , ie, immediately  butno later than 24 hours of when he or she becom es 
aware of it .
Once the investigators or other site personnel indicate an AE is serious in the electronic data 
capture (EDC) sy stem , an autom ated e -mail alert is sent to the designated [COMPANY_008] 
representative. If the EDC sy stem  is not available, then the Invest igator or other study  site 
staff reports a SAE to the appropriate [COMPANY_008] representative by [CONTACT_756]. The Sponsor 
representative will advise the Invest igator/study  site staff how to proceed.
The reference document for definit ion of expectedness/listedness is t he IB for the [COMPANY_008] 
investigat ional product and the [COMPANY_008] active comparator.
For further guidance on the definit ion of a SAE, see Appendix Bof the CSP.
8.3.9 Pregnancy
All pregnancies and outcomes of pregnancy should be reported to [COMPANY_008] except for:
If the pregnancy  is discovered before the study  parti cipant has received any  study  
intervent ion (see Exclusio n Cri teria, Secti on5.2)
Pregnancies in the partner of male participants.
[IP_ADDRESS] Maternal exposure
Female participants who are pregnant or have a confirmed posit ive pregnancy t est at screening 
or Day  1 will be excluded from the study  (see Sectio n5.2). If a participant beco mes pregnant 
during the course of the study , IP shoul d be di scontin ued immediately.
Pregnancy itself is not regarded as an AE unless there is a suspi[INVESTIGATOR_24510] n that the invest igational 
product under study  may have interfered with the effectiveness of a contraceptive medicat ion. 
Congenital abnormalit ies/birth defects and spontan eous miscarriages should be reported and 
handled as SAEs. Elective abortions without complicat ions should not be handled as AEs. The 
outcom e of all pregnancies (spontaneous miscarriage, elective terminat ion, ectopic pregnancy, 
norm al birth or congeni tal abnorm ality) shoul d be fo llowed up and documented even if the 
participant was discont inued fro m the study .
If any pregnancy  occurs in the course of the study , then the Invest igator or other site personnel 
informs the appropriate [COMPANY_008] representatives w ithin [ADDRESS_401825] igator to ensure that all relevant 
inform ation is provided to the [COMPANY_008] Patient Safet y data entr y site 
within 1 or 
5calendar days for SAEs (see Section 8.3.8 ) and within 30 days for all other pregnancies.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 62of 105The same timelines apply when outcome informat ion is available.
The PREGREP module in the eCRF is used to report the pregnancy and the paper based 
PREGOUT m odule is used to report the outcome of the pregnancy .
[IP_ADDRESS] Paternal exposure
There i s no restri ction on fathering children or donating sperm during the study .
8.3.10 Medication Error , Drug Abuse, and Drug Misuse
[IP_ADDRESS] Timelines
If an event of medication error, drug abuse, ordrug misuse occurs during the study , then the 
investigator or other site personnel informs the appropriate [COMPANY_008] representatives within 
one calen dar day , ie, immediately  but no later than [ADDRESS_401826] igator to ensure that all 
relevant informat ion is completed wi thin one(initial fatal/life-threatening or f ollow-up 
fatal/life-threatening) or 5 (other serious init ial and fo llow-up) calendar days if there is an 
SAE associated with the event of medicat ion error, drug abuse, or misuse (see Sect ion 8.3.8 ) 
and within 30 days for all other events.
[IP_ADDRESS] Medication Error
For the purposes of this clinical study  a medicat ion error is an unintended failure or mistake in 
the treatment process for an IMP or [COMPANY_008] NI MP that either causes harm to the 
participant or has the potential to cause harm to the participant.
The full definit ion and examples o f medication error can be found in Appendix B 4.
[IP_ADDRESS] Drug Abuse
Drug abuse is the persistent or sporadic intentional , non -therapeutic excessive use of IMP or 
[COMPANY_008] NIMP for a perceived reward or desired non -therapeuti c effect.
The full definit ion and examples o f drug abuse can be found in Appendix
 B 4.
[IP_ADDRESS] Drug Misuse
Drug misuse is the intentional and inappropriate use (by a st udy partici pant) of  IMP or 
[COMPANY_008] NIMP for medicinal purposes outside of the authorized product informat ion, or 
for unauthorized IMPs or [COMPANY_008] NIMPs, outside the intended use as specified in the 
protocol  and includes deliberate administration of the product by  [CONTACT_244972].
The full definit ion and examples o f drug misuse can be found in Appendix
 B 4.
Clinical Study Protocol -2.[ADDRESS_401827] igator is responsible for the detection and documentation of events meet ing the 
definit ions of Medical Device Deficiency that occur during the study  with such m edical 
devices.
The definit ion of a Medical Device Deficiency can be found in Appendix E.
NOTE: Incidents and deficiencies fulfilling the definit ion of an AE/SAE will also fo llow the 
processes outlined in
 Appendix Eof this protocol . 
The [COMPANY_008] or manufacturers medical device complaint report will be used to collect the 
deficiency. 
[IP_ADDRESS] Time period for detecting Medical Device Deficiencies
Medical devi ce incidents or m alfunct ions of the medical device will be detected, documented, 
and reported during all periods o f the study  in which the medical device is used.
If the Investigator learns of any Medical Device Deficiency at any  time after a participant h as 
been discharged from the study , and such incident is considered reasonably related to a 
medical device provided for the study , the Invest igator will pro mptly notify  the Sponsor.
The m ethod of docum enting Medical Device Deficiency is provided in Appendix E.
[IP_ADDRESS] Follow -up of Medical Device Deficiencies
Follow
-up applies to all participants, including those who discont inue study  intervent ion.
The Investigator is responsi ble for ensuring that follow -up includes any supplemental 
investigat ions as indicated to elucidate the nature and/or causalit y of the deficiency.
New or updated informat ion will be recorded on the originally co mpleted form wit h all 
changes signed and dated by [CONTACT_24342].
[IP_ADDRESS] Prompt reporting of Medical Device Deficiencies to Sponsor
Medical device deficiencies will be reported to the Sponsor within [ADDRESS_401828] for the receipt of Medical Device Deficiency reports.
[IP_ADDRESS] Regulatory reporting requirements for Medical Device Deficiencies
The Investigator will prompt ly report all medical device deficiencies occurring with any 
medical device provided for use in the study  in order for the Sponsor to fulfil the legal 
responsibilit y to notify appropriate regulatory  authori ties and other entit ies about certain 
safet y informat ion relating to medical devices being used in clinical studies.
The Investigator, or responsible person according to local requirements (eg, the head o f the 
medical inst itution), will comply wit h the applicable local regulatory  requi rements relating to 
the reporting of medical device deficiencies to the IRB/Independent Ethics Committee (IEC).
For further guidance on the definit ion of an SAE, see Appendix B 2of the CSP.
8.4 Overdose
For gui dance refer to [COMPANY_008] SOP Reporting of Individual Safet y Events in Clinical 
Studi es. 
More than 2 inhalat ions of BGF MDI (budesonide 160 micrograms/ glycopy rroni um bromide 
7.2 micrograms/ formoterol fumarate dihydrate 4.8 micrograms per actuati on) twice daily, in 
the morning and in the evening, is considered an overdose.
An overdose with associated AEs is recorded as the AE di agnosis/symptom s on the 
relevant AE m odules in the eCRF and on the Overdose eCRF module.
An overdose without associated symptoms is only  reported on the Overdose eCRF 
module.
If an overdose on an [COMPANY_008] study  intervent ion occurs in the cours e of the study , the 
Invest igator or other site personnel inform appropriate [COMPANY_008] representatives 
immediately , but no later than [ADDRESS_401829] igator to ensure that all 
relevant informat ion is provided to the [COMPANY_008] Patient Safet y data entry  site 
within one 
or 5 calendar days for overdoses associated with an SAE (see Section 8.3.8 ) and within 
30days for all other overdoses.
8.4.[ADDRESS_401830] frequent of which include blurred visio n, dry  mouth, nausea, headache, palpi[INVESTIGATOR_53895], 
and systolic hypertensio n. However, there we re no sy stemic ant icholinergic adverse effects 
following single inhaled doses up to 144 μg in patients with COPD.
8.4.3 Formoterol
An overdose of formoterol would likely lead to effects that are ty pi[INVESTIGATOR_21885] β 2-adrenergic 
agonists: tremor, headache, palpi[INVESTIGATOR_814], and tachycardia. Hy potensi on, metabo lic acidosis, 
hypokal emia, and hyperglycemia may  also occur. Supportive and symptomat ic treatment may 
be indicated. A dose of 90 μgadministered during 3 hours in patients with acute bronchial 
obstructi on raised no safe ty concerns.
If overdose occurs, including any  combinat ion of the above, the participant should be treated 
supportively with appropriate monitoring as necessary .
8.5 Optional Genomics Initiative Sample
Collect ion of opti onal samples for Genomics Init iative res earch is also part of this study  
as specified in the SoA and is subject to agreement in the ICF addendum.
A blood sam ple for DNA i solation will be collected fro m participants who have consented to 
participate in the genet ic analysis co mponent of the study at randomizat ion/baseline (Visit 3) 
(Table 1). Parti cipat ion is optional. Participants who do not wish to participate in the genet ic 
research may st ill part icipate in the study . Sam ples can be collected at any  time after the 
genet ic ICF is signed but is recommended at Visit 3.  
See Appendix Dfor inform ation rega rding genetic research. 
Details on processes for 
collect ion and shipment and destruction of these samples are provided in Appendix Dand in 
the Labor atory  Manual. 
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 66of 1059 STATISTICAL CONSIDER ATIONS
9.1 Statistical Hypotheses
No formal stati stical hypotheses will be tested.
9.2 Sample Size Determination
9.3 Populations for Analyses
For the purposes of analysis, the fo llowing popul ations are defined:
Table [ADDRESS_401831] ion will apply  to both the 12 -week study and 52- week 
study , unless specified otherwise.
Details o f all stati stical analyses will  be doc umented in the Statistical Analysis Plan (SAP). 
The SAP will be finalized prior to unblinding o f the data for the analysis. 
9.4.[ADDRESS_401832] 
deviat ion, median, minimum, and maximum, and quartiles where appropriate. 
9.4.2 Efficacy Analysis
[IP_ADDRESS] Exploratory CAT assessment
The CAT assessment will be summarized by [CONTACT_10659] . The change from  baseline in 
CAT total score will be summarized by  [CONTACT_325396]. 
9.4.3 Safety Analysis
The safet y analyses will be based on the safet y analysis sets and will include all the patients 
who had received at minimum one exposure to the intervent ion. All AEs should be reported, 
whether or not they  are considered to be related to treatment. All available data in the study  
popul ation shoul d be accounted for in the evaluat ion. Exposure extent, safet y, and tol erabili ty 
will be co mpared qu alitatively and reported between arms. The fo llowing will be reported:
All AEs beginning during the treatment or fo llow-up period will be summarized descript ively 
by [CONTACT_2939], at the level o f the MedDRA PT and SOC, for the Safet y analysis sets. The 
summar ies for each treatment arm will include the number and percentage of participants 
experiencing the event and the number of events. 
For AEOSIs, AEs leading to discont inuation o f IP, and SAEs, exposure -adjusted incident rates 
and the associated 95% CI w ill be presented. The rate difference between treatment arms and 
the associ ated 95% CIs will also be reported. No formal hypothesis tests will be performed. 
Details will be provided in the statist ical analysis plan.
Addit ional safet y variables, such as con comitant medi cations, vital signs, physical 
examinat ion, clinical laboratory , and ECG status will be summarized wit h the percentage of 
patients in different categories.
Clinical Study Protocol -2.[ADDRESS_401833] ics and qualitat ive summaries. In addit ion to all AEs, the summary will include SAEs, 
AEs leading to treatment discont inuat ion, and AEOSIs as defined in Section 8.3.6 .
Paradoxical Bronchospasm -The exposure -adjusted i ncidence rate of paradoxical 
bronchospasm (defined in AEOSI Section 8.3.6 )
 will be summarized. The rate 
difference between treatment arms and the 95% CI will be evaluated. 
[IP_ADDRESS] 12-lead ECG
Summary  statistics for absol ute values and change fro m baseline will be tabulated by [CONTACT_325397]. For analysis of 12- lead ECG 
param eters, baseline will be defined as the mean of the latest triplicate measu rements 
extracted from the Holter monitor at [ADDRESS_401834] igator, 12-lead ECG parameter baseline values are 
defined as those collected at screening (Visit 1).
[IP_ADDRESS] Digital 12
-lead Holter ECG 
Summary  statistics for raw values and changes from baseline in QTcF intervals will be 
calculated. The assessments will be tabulated for each treatment and assessment time. 
Baseline definit ion and details o f digital 12 -lead Holter ECG analyses will be provided in the 
SAP.
[IP_ADDRESS] Clinical laboratory values
Summary  statistics of change from baseline values will be tabulated for each treatment and 
scheduled assessment time. For clinical laboratory  measurements, baseline will be defined as 
the last available value prior to dosing on the day  of or pri or to randomizat ion. Potenti ally 
clinically significant values will be ident ified and summarized. 
[IP_ADDRESS] Vital signs
Summary  statistics of change from baseline will be tabulated by  [CONTACT_325398]. For vital signs, baseline will be defined as the 
last available value prior to dosing on the day of or pri or to randomization. In addit ion, 
potenti ally clinically significant values will be ident ified and summarized. 
[IP_ADDRESS] Spi[INVESTIGATOR_325350] o f FEV1 post -dose evaluation at 5, 15, 30, 60 minutes with pre -dose FEV1 
obtained on the sa me day will be summarized.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D 5985C00003
CONFIDENTIAL AND PROPRIETARY 69of 1059.5 Interim Analyses 
No Interim Analysis is applied to this study . 
9.6 Data Monitoring Committee
Not applicable -no DMC is planned. 
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 70of [ZIP_CODE] SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS
Appendix ARegulatory, Ethical, and Study Oversight Cons iderations
A 1 Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for I nternational Organizat ions of Medical 
Sciences Internat ional Ethical Guidelines
Applicable Internat ional Council for Harmonisation (ICH) GCP Guidelines
Applicable laws and regulations
The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant 
docum ents (eg, adverti sements) m ust be submitted to an IRB/IEC by  [CONTACT_325399] (IRB)/IEC before the study  is 
initiated.
Any amendments to the protocol will require IRB/IEC and applic able Regulatory  
Authori ty approval  before implementati on of  changes m ade to the study  design, except 
for changes necessary  to eliminate an immediate hazard to study  parti cipants.
[COMPANY_008] will be responsible for obtaining the required authorizat ions to conduct the 
study  from the concerned Regulatory  Authori ty. This responsibilit y may be delegated to a 
Contract Research Organization but the accountabilit y remains wi th [COMPANY_008].
The Investigator will be responsible for providing oversight of the conduct of the study  at 
the site and adherence to requirements of 21 Code of Federal Regulat ions (CFR), ICH 
guidelines, the IRB/IEC, European Regulat ion 536/2014 for clinical studies (if 
applicable), European Medical Device Regulat ion 2017/745 for clinical device research 
(if applicable), and all other applicable local regulations
Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by [CONTACT_208555] a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards th e safet y of parti cipants and the safet y of 
a study  intervent ion under clinical invest igation are m et.
The Sponsor has a legal responsibilit y to notify  both the l ocal regulatory  authori ty and 
other regulatory  agencies about the safet y of a study  intervent ion under clinical 
investigat ion. The Sponsor will co mply wi th country -specific regulatory  requi rements 
relating to safet y reporting to the regulatory  authorit y, IRB/IEC, and invest igators.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 71of 105For all studies except those utilizing medical devices, I nvest igator safet y reports m ust be 
prepared for suspected unexpected serious adverse reactions according to local regulatory  
requi rements and Sponsor policy and forwarded to invest igators as necessary.
European Medical Device Regulat ion 2017/745 for clinical device research (if 
applicable), and all other applicable local regulat ions
An Invest igator who receives an Investigator safety report describing a SAE or other 
specific safet y informat ion (eg, summary or list ing of SAEs) fro m the Sponsor will 
review and then file it along wit h the IB and will notify the IRB/IEC, if appropriate 
according to local requirements.
Regulatory Reporting Requirements for Serious Breaches of Protocol or GCP
Prom pt notificat ion by [CONTACT_325400] (po tential ) seri ous breach of the 
protocol  or regul ations is essent ial so that l egal obligat ions and ethical obligat ions are met.
A “serious breach” means a breach likely to affect to a significant degree the safet y and 
rights of a participant or the reliabil ity and robustness of the data generated in the clinical 
trial.
[COMPANY_008] will comply wit h country -specific regulatory  requi rements rel ating to serious 
breach reporting to the regulatory  authori ty, IRB/IEC, and Invest igators.
Where the EU Clinical Trials Regulat ion 536/[ADDRESS_401835] 
processes to enter details o f serious breaches into the European Medicines Agency  CTIS. 
It is important to note that redacted versions of serious breach reports will be available to 
the public via CTIS .
If any (potential) serious breach occurs in the course of the study , Invest igators or other site 
personnel will inform the appropriate [COMPANY_008] representatives immediately.
In certain regions/countries, [COMPANY_008] has a legal responsibilit y to notify both the local 
regul atory  authori ty and other regul atory  agencies about such breaches.
The invest igator should have a process in place to ensure that:
The site staff or service providers delegated by [CONTACT_093]/inst itution are able to 
ident ify the o ccurrence of a (potential) serious breach.
A (potential) serious breach is pro mptly reported to [COMPANY_008] or delegated party, 
through the contacts (e -mail address or telephone number) provided by [CONTACT_38227].
A [ADDRESS_401836] igators will provide the Sponsor with sufficient, accurate financial 
inform ation as requested to allow the Sponsor to submit complete and accurate financial 
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 72of 105certification or disclosure statements to the appropriate regulatory  authori ties. Investi gator s 
are responsible for providing information on financial interests during the course of the study 
and for 1 y ear after com pletion of  the study .
A 3 Informed Consent Process
The Investigator or his/her representative will explain the nature of the study  to the 
participant or his/her legally  authori zed representative and answer all quest ions regarding 
the study .
Parti cipants or thei r legally  authori zed representative must be informed that their 
participat ion is voluntary, and they  are f ree to refuse to participat e and may  withdraw 
their consent at any  time and for any  reason during the study . The parti cipant's l egally 
authori zed representative will be required to sign a statement of informed consent that 
meets the requirements of [ADDRESS_401837] requirements, where applicable, and the IRB/IEC or 
study  center.
The m edical  record m ust include a statem ent that wri tten inform ed consent was obtained 
before the participant was enrolled in t he study  and the date the written consent was 
obtained. The authorized person obtaining the info rmed consent must also sign the ICF.
Parti cipants m ust be re -consented to the most current version of the ICF(s) during their 
participat ion in the study.
A copy of the ICF(s) m ust be provi ded to the participant’s legally  authori zed 
representative.
Parti cipants who are rescreened are required to sign a new ICF (or signed by [CONTACT_325401]).
A 4 Data Protection
Parti cipants will be assigned a unique ident ifier by [CONTACT_1034]. Any participant records 
or datasets that are transferred to the Sponsor will contain the ident ifier only; part icipant 
names or any  information which would make the participant ident ifiable w ill not be 
transferred.
The parti cipant or thei r legally  authori zed representative must be informed that his/her 
personal study -related data will be used by [CONTACT_325402]. The level o f disclosure and use of their data m ust al so be explained to the 
participant or their legally  authori zed representative in the informed consent 
The parti cipant or thei r legally  authori zed representative must be informed that his/her 
medical records may be examined by [CONTACT_17080] y Assurance auditors or other 
authori zed personnel appointed by  [CONTACT_1034], by [CONTACT_17081]/IEC m embers, and by  
[CONTACT_32857].
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 73of 105The parti cipant must be inform ed that data will be collected only  for the business needs. 
We will only collect and use the minimum amount of personal data to support our 
business act ivities and will not make personal data available to any one (including internal 
staff) who is not authorized or does not have a business need to know the informat ion. 
The part icipant must be informed that in so me cases their data may be pseudonymized. 
The General Data Protection Regulat ion defines pseudonymizat ion as the processing of 
personal data in such a way  that the personal  data can no longer be attributed to a specific 
individual  without the use of addit ional informat ion, provi ded that such addit ional 
inform ation is kept separately and protected by  [CONTACT_325403].
Personal Data Breaches
A ‘personal data breach’ means a breach of security  leading to the accidental or unlawful 
destruction, loss, alteration, unauthorized disclosure of, or access to, personal data transmitted, 
stored or otherwise process ed.
In com pliance wi th applicable l aws, the Data Controller1for the processing act ivity where 
the personal data breach occurred ([COMPANY_008] or respectively the site), will notify the 
data protecti on authori ties wi thout undue delay  within the legal terms provi ded for such 
notification and wit hin the prescribed form and content.
                                               
1The data controller determines the purposes for which and the means by [CONTACT_325404], as defined by [CONTACT_325405] -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 74of 105While [COMPANY_008] has processes in place to deal with personal data breaches it is 
important that invest igators that work with [COMPANY_008] have controls in place to protect 
patient data privacy.
The Investigator should have a process in place to ensure that:
allow site staff or service providers delegated by  [CONTACT_3170]/inst itution to i dentify the 
occurrence of a (potential) personal data breaches.
any (potential) personal data breach is prompt ly reported to [COMPANY_008] or delegated 
party , through the contacts (e -mail address or telephone number) provided by  
[CONTACT_38227].
[COMPANY_008] and the site must demonstrate that they:
have taken all necessary  steps to avoi d personal data bre aches and 
have undertaken measures to prevent such breaches from occurring in the first place and 
to mit igate the impact of occurred data breaches (eg, applying encrypt ion, maintaining 
and keepi[INVESTIGATOR_325351] y measures up -to-date, regular revie ws and testing, 
regul ar training of emplo yees, and developed securit y policies and standards).
where possible, have developed an internal data breach reporting and invest igation 
process and internal protocols wit h gui dance on how to respond swift ly and dil igently to 
the occurrence of a personal data breach.
where it has not been possible to develop an internal data breach reporting and 
investigat ion process, the site fo llows [COMPANY_008]’s instructions.
Notification of Personal Data Breach to Participants:
Notificat ion to participants is done by [CONTACT_325406], the 
notification is done in co llaboration with the site and is performed by [CONTACT_5753]/or 
Principal Investigator, acting on behalf o f [COMPANY_008], so that [COMPANY_008] has no access 
to the i dentifying personal informat ion of the participants. The s ite and/or Principal 
Invest igator shall conduct the notificat ion by [CONTACT_325407].
If a personal data breach occurs in a processor’s systems, engaged by [CONTACT_38227], the 
processor under con tractual  obligat ions wit h [COMPANY_008] prompt ly and in due course 
after di scovering the breach notifies [COMPANY_008] and provides full cooperation with the 
investigat ion. In these cases, to the extent [COMPANY_008] is the Data C ontroller for the 
processing activit y where the breach occurred, it will be responsible for the notificat ion to 
data protecti on authori ties and, if applicable, to participants. If the personal data breach 
needs to be notified to the participants, the notif ication to parti cipants is done in 
Clinic al Study  Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 75of 105collaboration with the site and is performed by [CONTACT_5753]/or Principal Invest igator, 
acting on behalf of the Sponsor, so that [COMPANY_008] has no access to the identifying 
personal informat ion of the participants.
If a personal data breach invo lving an [COMPANY_008]'s representative device (ie, Study 
Moni tor laptop), [COMPANY_008] representative will provide [COMPANY_008] with all of the 
inform ation needed for notificat ion of the breach, without disclosing data that allows 
[COMPANY_008] direct ly or indirect ly to ident ify the participants. The notificat ion will be 
done by  [CONTACT_325408] a risk of re- ident ificat ion ofthe 
participants. If the data breach must be notified to the data subjects, the notificat ion will 
be done direct ly by [CONTACT_325409]/or Principal 
Invest igator, acting on behalf o f the Sponsor, so that [COMPANY_008] has no access to the 
ident ifying personal informat ion of the participants. The contract between [COMPANY_008] 
and the Study  Moni tor shall expressly  specify these condi tions.
The contract between the site and [COMPANY_008] for performing the clinical research 
inclu des the provisio ns and rules regarding who is responsible for coordinat ing and 
directing the actions in relat ion to the breaches and performing the mandatory  
notifications to authorities and participants, where applicable.
A 5 Committees Structure
The safet y of all Sponsor clinical studies is closely monitored on an ongoing basis by [CONTACT_325410] y. Issues ident ified will be addressed; for 
instance, this could invo lve amendments to the CSP and letters to investigators. 
A [ADDRESS_401838] ical analysis is not relevant.
A descript ion of this clinical study  will be available on www.astrazenecaclinicaltrials.com as 
well as https://euclinicaltrials.eu and http://www.clinicaltrials.gov, as will the summary o f the 
study  resul ts when they  are available. The clinical study  and/or summary of study  resul ts may  
also be available on other websites according to the regulations of the countries in which the 
study  is conducted.
A 7 Data Quality Assurance
All participant data relat ing to the st udy will be recorded on eCRF unless transmitted to 
the Sponsor or designee electronically  (eg, l aboratory  data). The Investigator is 
Clinical Study Protocol -2.[ADDRESS_401839] by  [CONTACT_122642].
The Investigator m ust m aintain accurate documentation (source data) that supports the 
inform ation entered in the eCRF.
The Investigator must permit study -related m onitoring, audi ts, IRB/IEC review, and 
regul atory  agency inspecti ons and provi de di rect access to source data d ocum ents.
Moni toring details describing strategy  (eg, risk -based init iatives in operations and qualit y 
such as Risk Management and Mit igation Strategies and Analyt ical Risk-Based 
Moni toring), m ethods, responsibilit ies and requirements, including handling o f 
nonco mpliance issues and monitoring techniques (central, remote, or on -site monitoring) 
are provided in the Moni toring Plan .
The Sponsor or designee is responsible for the data management of this study  including 
qualit y checking of the data.
The Sponsor assumes accountabilit y for acti ons delegated to other individuals (eg, 
Contract Research Organizations).
Study  monitors will perform  ongoing source data verification to confirm that data entered 
into the eCRF by [CONTACT_1191], comp lete, and verifiable fro m 
source documents; that the safet y and ri ghts of  participants are being protected; and that 
the study  is being conducted in accordance with the currently approved protocol and any 
other study  agreem ents, ICH GCP, and all applicable regul atory  requi rements.
Records and documents, including signed ICFs, pertaining to the conduct of this study  
must be retained by [CONTACT_325411] a minimum o f 25years after study archiving or as 
requi red by l ocal regulat ions, according to the Astra Zeneca Glo bal Retent ion and 
Disposal  Schedule. No records m ay be destroyed during the retention period without the 
written approval  of [COMPANY_008]. No records may  be transferred to another locat ion or 
party  without wri tten notificat ion to [COMPANY_008].
A 8 Sour ce Documents
Source documents provide evidence for the existence of the participant and substantiate 
the integrit y of the data collected. Source documents are filed at the Invest igator’s site.
Data entered in the eCRF that are transcribed from source docum ents m ust be consistent 
with the source documents or the discrepancies must be explained. The Invest igator may 
need to request previous medical records or transfer records, depending on the study. 
Also, current medical records must be available.
A [ADDRESS_401840] igator may include but 
are not limit ed to:
Failure of the Invest igator to comply wit h the protocol, the requirements of the IRB/IEC 
or local health authori ties, the Sponsor's procedures, or GCP guidelin es
Inadequate recruit ment of parti cipants by  [CONTACT_11856]
Discontinuati on of  further study  intervent ion developm ent
If the study  is prem aturely  terminated or suspended, the Sponsor shall prompt ly inform the 
investigators, the IECs/IRBs, the regulatory authorit ies, and any contract research 
organi zation(s) used in the study  of the reason for terminat ion or suspensio n, as specified by 
[CONTACT_122644]. The Invest igator shall pro mptly inform the participant 
and should assure appropri ate parti cipant therapy  and/or foll ow-up.
Parti cipants from  terminated si tes will  have the opportuni ty to be transferred to another site to 
continue the study .
A 10 Publication Policy
The results of this study  may be published or presented at scient ific meet ings. If this is 
foreseen, the Invest igator agrees to submit all manuscripts or abstracts to the Sponsor 
before submissio n. This allows the Sponsor to protect proprietary  information and to 
provi de comments.
The Sponsor will co mply with the requi rements for publicat ion of study  resul ts. In 
accordance with standard editorial and ethical practice, the Sponsor will generally support 
publicat ion of mult i-center studi es only  in thei r entir ety and not as individual site data. In 
this case, a coordinat ing Invest igator will be designated by [CONTACT_11402].
Authorship will be determined by  [CONTACT_73008] h Internat ional 
Committee of Medical Journal Editors authorship requirem ents.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 78of 105Appendix BAdverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
B [ADDRESS_401841] a causal 
relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
(eg, an abnormal laboratory  finding), symptom (eg, nausea, chest pain), or disease temporally  
associ ated wi th the use of a m edicinal product, whether or not considered related to the 
medicinal product. 
The term  AE is used to include both serious and non -serious AEs and can include a 
deteri oration of  a pre -exist ing medical occurrence. An AE may  occur at any  time, including 
run-in or washout periods, even if no study  intervent ion has been administered.
B 2 Definition of Serious Adverse Events
An SAE is an AE occurring during any study  phase (i e, run -in, treatment, washout, follow -
up), that fulfills one or more of the following cri teria:
Results in death
Is immediately life -threatening
Requi res in -partici pant hospi [INVESTIGATOR_325352] 
Results in persistent or significant disabilit y or incapaci ty 
Is a congenital ano maly or bi rth defec t
Is an important medical event that may jeopardize the participant or may require medical 
treatm ent to prevent one of the outcomes listed above.
Adverse events for malignant tumors reported during a study  shoul d generally be assessed as 
Serious AEs . If no other seriousness criteria apply, the ‘Important Medical Event’ criterion 
shoul d be used. In certain situat ions, however, medical judgment on an individual event basis 
shoul d be applied to clarify  that the malignant tumor event should be assessed and rep orted as 
a non-serious AE . For exam ple, if the tum or is included as medical history  and progressi on 
occurs duri ng the study , but the progression does not change treatment and/or prognosis of the 
malignant tumor, the AE may  not fulfill the attributes for be ing assessed as serious, although 
reporting of the progression of the malignant tumor as an AE is valid and should occur. Also, 
some ty pes of  malignant tum ors, which do not spread remotely after a routine treatment that 
does not require hospi[INVESTIGATOR_3094], may be assessed as non -serious; examples in adult s include 
Stage 1 basal cell carcino ma and S tage 1A1 cervical cancer removed via cone biopsy .
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 79of 105Life-threatening
‘Life -threatening’ means that the participant was at immediate risk of death from the AE as it 
occurred or it is suspected that use or continued use of the product would result in the 
participant’s death. ‘Life -threatening’ does not m ean that had an AE occurred in a more severe 
form it might have caused death (eg, hepatit is that resolved wit hout hepati c failure).
Hospi[INVESTIGATOR_96698] a serious AE, although the reasons 
for it may be (eg, bronchospasm, laryngeal edema). Hospi[INVESTIGATOR_33094]/or surgical 
operati ons planned before or during a study  arenot consi dered AEs if the illness or disease 
existed before the participant was enrolled in the study , provi ded that i t did not deteri orate in 
an unexpected way  during the study .
Important Medical Event or Medical Treatment
Medical and scientific judgment should be exercised in deciding whether a case is serious in 
situations where important m edical events may  not be immediately life threatening or result in 
death, hospi [INVESTIGATOR_3094], disabilit y or incapaci ty but may jeopardize the parti cipant or m ay 
requi re medical treatm ent to prevent one or more outcomes listed in the definit ion of seri ous. 
These should usually be considered as serious.
Simply stoppi[INVESTIGATOR_33095]; medical 
judgment must be used.
Angio edema not severe enough to require intubation but requiring iv hydrocortisone 
treatm ent
Hepatotoxicit y caused by [CONTACT_33153] l (acetaminophen) overdose requiring treatment with 
N-acetylcysteine
Intensive treatment in an emergency room or at home for allergic bronchospasm
Blood dy scrasias (eg, neutropenia or anemia requiring blood transfusio n, etc.) or 
convulsio ns that do not result in hospi[INVESTIGATOR_3094]
Development of drug dependency or drug abuse
Intensity Rating Scale:
Mild (awareness of sign or symptom, but easily tolerated)
Moderate (di scomfort sufficient to cause interference with normal act ivities)
Severe (incapacitat ing, with inabilit y to perform  norm al activities)
It is important to dist inguish between serious and severe AEs. Severit y is a measure of 
intensi ty whereas seri ousness is defined by [CONTACT_73010] B 2 . An AE of severe 
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 -D5985C00003
CONFIDENTIAL AND PROPRIETARY 80of 105intensity need not necessarily be considered serious. For ex ample, nausea that persists for 
several hours may  be consi dered severe nausea, but not a SAE unless it meets the criteria 
shown in Appendix B 2. On the other hand, a stroke that results in only a limited degree of 
disabili ty may be considered a mild stroke but would be a SAE when it satisfies the criteria 
shown in Appendix  B
2.
B 3 A Guide to Interpreting the Causality Question
When making an assessment of causalit y consi der the foll owing f actors when deciding if there 
is a ‘reasonable possibilit y’that an AE m ay have been caused by [CONTACT_33641].
Time Course. Exposure to suspect drug. Has the participant actually received the suspect 
drug? Did the AE occur in a reasonable temporal relat ionship to the administration of the 
suspect drug?
Consistency wit h known drug profile. Was the AE consistent with the previous 
knowl edge of the suspect drug (pharmaco logy and toxi cology) or drugs of the same 
pharmaco logical class? Or could the AE be ant icipated from its pharmaco logical 
properties?
De-challenge experience. Did the AE resolve or improve on stoppi[INVESTIGATOR_325353]?
No al ternative cause. The AE cannot be reasonably explained by [CONTACT_33154], other drugs, other host or environmental factors.
Re-challenge experi ence. Di d the AE reoccur if the suspected drug was reintroduced after 
having been stopped? [COMPANY_008] would not normally reco mmend or support a re-
challenge .
Laboratory  tests. A specific laboratory  invest igation (if performed) has confirmed the 
relationship .
In difficult cases, other factors co uld be considered such as:
Is this a recogni zedfeature of overdose of the drug?
Is there a known mechanism?
Causalit y of ‘related’ is m ade if fo llowing a review of the relevant data, there is evidence for a 
‘reasonable possibilit y’of a causal relationship for the individual case. The expressio n 
‘reasonable possibilit y’ of acausal relationship is meant to convey, in general, that there are 
facts (evidence) or arguments to suggest a causal relat ionship.
Clinical Study Protocol -2.[ADDRESS_401842] a 
causal relat ionship, the event(s) will be assessed as ‘not related’.
Causal relat ionship in cases where the DU S has deteriorated due to lack of effect should be 
classified as no reasonable possibilit y.
B 4 Medication Error, Drug Abuse, and Drug Misuse
Medication Error
For the purposes of this clinical study  a medicat ion error is an unintended failure or mistake in 
the treatment process for an [COMPANY_008] study  intervent ion that either causes harm to the 
participant or has the potential to cause harm to the participant. 
A medicat ion error is not lack of efficacy o f the drug, but rather a human or process related 
failure while the drug is in control of the study  site staff or parti cipant.
Medicat ion error includes situat ions where an error. 
Occurred
Was identified and intercepted before the participant received the drug
Did not occur, but circumstances were recognized that could have led to an error
Examples of events to be reported in clinical studies as medication errors:
Drug name [CONTACT_33165] n
Dispensing error eg, medica tion prepared incorrectly , even if i t was not actually  given to 
the participant
Drug not administered as indicated, for example, wrong route or wrong site of 
administration
Drug not taken as indicated eg, tablet disso lved in water when it should be taken a s a 
solid tablet 
Drug not stored as instructed eg, kept in the fridge when it should be at room temperature 
Wrong participant received the medicat ion (excluding IRT/RTSM errors)
Wrong drug administered to participant (excluding IRT/RTSM errors)
Examples of events that do not require reporting as medicat ion errors in clinical studies:
Errors related to or resulting fro m IRT/RTSM -including those which lead to one of the 
above listed events that would otherwise have been a medication error 
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 82of 105Parti cipant ac cidentally  missed drug dose(s) eg, forgot to take medication
Accidental  overdose (will be captured as an overdose)
Parti cipant f ailed to return unused medicat ion or empt y packaging
Errors related to background and rescue medicat ion, or standard -of-care m edication in 
open l abel studi es, even if an [COMPANY_008] product 
Medicat ion errors are not regarded as AEs, but AEs may occur as a consequence of a 
medicat ion error.
Drug Abuse
For the purpose of this study , drug abuse is defined as the persistent or sporadi c intent ional, 
non-therapeut ic excessive use of IMP or [COMPANY_008] NIMP for a perceived reward or desired 
non-therapeut ic effect.
Any events of drug abuse, with or without associated AEs, are to be captured and forwarded 
to the data entry  site using the Drug Abuse Report Form. This form should be used both if the 
drug abuse happened in a study  parti cipant or if the drug abuse involves a person not enrolled 
in the study  (such as a rel ative of the study  parti cipant).
Examples of drug abuse include but are not limited to:
The drug is used with the intent of getting a perceived reward (by [CONTACT_244988] 
a person not enrolled in the study ).
The drug in the form o f a tabl et is crushed and injected or snorted with the intent of 
getting high.
Drug Misuse
Drug misuse is the intent ional and inappropriate use (by  a study parti cipant) of IMP or 
[COMPANY_008] NIMP for medicinal purposes outside of the authorized product informat ion, or 
for unauthorized IMPs or [COMPANY_008] NIMPs, outside the intended use as specified in the 
protocol  and includes deliberate administration of the product by  [CONTACT_244972].
Events of drug misuse, with or without associated AEs, are to be captured and forwarded to 
the data entry  site using the Drug Misuse Report Form. This form shoul d be used both if the 
drug misuse happened in a study  parti cipant or if the drug misuse regards a person not 
enrolled in the study  (such as a relative of the study  parti cipant).
Examples of drug misuse include but are not limited to:
The drug is used with the intent ion to cause an effect in another person.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 83of 105The drug is so ld to other people for recreational purposes.
The drug is used to facilitate assault in another person.
The drug is deliberately administered by [CONTACT_244972].
The drug is split in h alf because i t is easier to swallow, when it is stated in the protocol 
that it must be swallowed whole.
Only half the dose is taken because the study  partici pant feels that he/she is feeling better 
when not taking the who le dose.
Someone who i s not enrolle d in the study  intentionally  takes the drug.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 84of 105Appendix CHandling of Human Biological Samples
C 1 Chain of Custody
A full chain o f custody  is maintained for all samples throughout their lifecycle.
The Investigator keeps full traceabilit y of collected bi ological samples f rom the participants 
while in storage at the center until shipment or disposal (where appropriate) and records 
relevant processing informat ion related to the samples while at site.
The sample receiver keeps full traceabilit y of the sam ples while in storage and during use unt il 
used or disposed of or until further shipment and keeps record of receipt of arrival and onward 
shipment or disposal.
[COMPANY_008] or delegated representatives will keep oversight of the ent ire life cycle through 
internal  procedures, m onitoring of study  sites, auditing or process checks, and contractual 
requi rements of external laboratory  provi ders
Samples retained for further use will be stored in the [COMPANY_008]- assigned biobanks or other 
sample archive facilit ies and will be tracked by [CONTACT_325412].
C 2 Withdrawal of Informed Consent for Donated Biological Samples 
If a participant withdraws consent to the use of donated bio logical  samples, the sam ples will 
be disposed of/destroy ed/repatriated, and the action documented. If samples are already  
analyzed ,[COMPANY_008] is not obliged to destroy  the resul ts of this research.
Following wi thdrawal  of consent for bio logical samples, further study  partici pation shoul d be 
consider ed in rel ation to the wi thdrawal  processes outlined in the informed consent.
The Investigator:
Ensures participant’s withdrawal of informed consent to the use of donated samples is 
highlighted immediately to [COMPANY_008] or delegate.
Ensures that relevant human bio logical samples from  that parti cipant, if stored at the 
study  site, are immediately  identified, disposed of as appropriate, and the action 
docum ented.
Ensures that the participant and [COMPANY_008] are informed about the sample disposal.
AstraZenec a ensures the organizat ion(s) ho lding the samples is/are informed about the 
withdrawn consent immediately and that samples are disposed of or repatriated as appropriate, 
and the action is documented and study  site is notified.
Clinical Study Protocol -2.[ADDRESS_401843] SAMPLES
International Airline Transportation Associat ion (IATA) 
(https://www.iata.org/whatwedo/cargo/dgr/Pages/download.aspx ) classifies infect ious 
substances into 3 categories: C ategory  A, Category B or Exempt
Category A Infectious Substances are infect ious substances in a form that, when exposure to 
it occurs, i s capable of causing permanent disabilit y, life-threatening or fatal  disease in 
otherwi se healt hy humans or animals. 
Category A Pathogens are, eg, Ebola, Lassa fever virus. Infect ious substances meet ing these 
criteria which cause disease in humans or both in humans and animals must be assigned to 
UN2814. Infect ious substances which cause disease only in animals must be as signed to 
UN2900.
Category B Infectious Substances are infect ious Substances that do not meet the criteria for 
inclusio n in Category  A. Category  B pathogens are, eg, Hepatitis A, C, D, and E viruses. They  
are assigned the fo llowing UN number and proper sh ippi[INVESTIGATOR_72919]:
UN 3373 –Biological Substance, Category  B
are to be packed in accordance with UN [ADDRESS_401844] to these regulat ions unless they  
meet the criteria for inclusio n in another class.
Clinical study samples will fall into Category  B or exempt under IATA regulat ions
Clinical study  samples will routinely  be packed and transported at ambient temperat ure 
in IATA 650 compliant packaging 
(https://www.iata.org/whatwedo/cargo/dgr/Documents/DGR -60-EN-PI650.pdf ).
Biological samples transported in dry  ice requi re addi tional dangerous goods 
specification for the dry  ice content
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 86of 105Appendix DOptional Genomics Initiative Sample
D 1 Use/Analysis of DNA
[COMPANY_008] intends to collect and store DNA for genet ic research to explore how genetic 
variat ions may affect clinical parameters, risk and prognosis o f diseases, and the response 
to medicat ions. This genetic research may lead to better understanding of d iseases, better 
diagnosis of diseases or other improvements in healt h care and to the discovery o f new 
diagnosti cs, treatm ents or m edicat ions. Therefore, where local regulat ions and IRB/IEC 
allow, a blood sample will be collected for DNA analysis from cons enting participants.
This optional genet ic research may consist of the analysis o f the structure of the 
participant´s DNA, i e, the enti re genom e. 
The results of genet ic analyses may be reported in a separate study summary.
The Sponsor will store the DNA s amples in a secure storage space with adequate measures 
to protect confidentialit y.
D 2 Genetic Research Plan and Procedures
Selection of Genetic Research Population
All participants will be asked to participate in this genet ic research. Participat ion is 
voluntary and if a participant declines to participate there will be no penalt y or loss of 
benefit. The participant will not be excluded fro m any aspect of the main study .
Inclusion Criteria
For inclusio n in this genet ic research, participants must fulfill al l of the inclusio n criteria 
described in the main body  of the CSP and: Provi de inform ed consent for the Geno mics 
Initiative sampling and analyses.
Exclusion Criteria
Exclusio n from this genet ic research may be for any o f the excl usion criteria specified in
the main study  or any  of the f ollowing:
Withdrawal of Consent for Genetic Research
Parti cipants may  withdraw from  this genet ic research at any t ime, independent of any 
decisio n concerning participation in other aspects of the main study . Vol untary  withdrawal 
will not prejudice further treatment. Procedures for withdrawal are outlined in Sect ion 7.2.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 87of 105Collection of Samples for Genetic Research
The blo od sam ple for this genetic research will be obtained from the participants at Visit [ADDRESS_401845] 
study  visit. Only  one sample shoul d be co llected per participant for genet ics during the 
study .
Coding and Storage of DNA Samples
The processes adopted for t he coding and storage of samples for genet ic analysis are 
important to maintain participant confident iality. Sam ples will  be stored for a m aximum  of 
[ADDRESS_401846] visit, after which they  will be destroy ed. 
DNA is a finite resource that i s used up during analyses. Samples will be stored and used 
until no further analyses are possible or the maximum storage time has been reached.
An addit ional second code will be assigned to the sample eit her before or at the time of 
DNA ext raction repl acing the informat ion on the sample tube. Thereafter, the sample will 
be ident ifiable only by [CONTACT_33160], unique number. This number is used to identify the 
sample and corresponding data at the [COMPANY_008] genet ics laboratori es, or at the 
designated organizat ion. No personal details identifying the individual will be available to 
any person ([COMPANY_008] emplo yee or desi gnated organi zations working wit h the DNA).
The link between the participant enrollment/randomizat ion code and the second number
will be maintained and stored in a secure environment, with restricted access at 
[COMPANY_008] or designated organizations. The link will be used to identify the relevant 
DNA samples for analysis, facilitate correlat ion of genoty pic resul ts wi th clinical da ta, 
allow regulatory  audi t, and permi t tracing of samples for destruction in the case of 
withdrawal  of consent.
Ethical and Regulatory Requirements
The principles for ethical and regulatory  requi rements for the study , incl uding this genet ics 
research component, are outlined in Appendix A.
Inform ed Consent
The genetic component of this study  is opti onal and the parti cipant m ay part icipate in 
other components of the main study  without parti cipating in this genet ic component. To 
participate in the genet ic component of the study the participant must sign and date both 
the consent form for the main study  and the addendum  for the Genomics Init iative 
component of the study . Copi [INVESTIGATOR_325354] -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 88of 105the participant and the original filed at the study  center. The PI(s) is responsible for 
ensuring that consent is given freely and that the participant understands that they  may 
freely  withdrawal  from the genet ic aspect of the study at any t ime.
Participant Data Protection
[COMPANY_008] will not provide individual genoty pe results to parti cipants, any  insurance 
company, any emplo yer, thei r family members, general physician unless required to do so 
by [CONTACT_2371].
Extra precautions are taken to preserve confident iality and prevent genetic data being 
linked to the ident ity of the parti cipant. In except ional circumstances, however, certain 
individuals might see both the genet ic data and the personal ident ifiers of a participant. For 
example, in the case of a medical emergency , an [COMPANY_008] Physician or an Invest igator 
might know a part icipant’s ident ity and also have access to his or her genet ic data. 
Regulatory  authori ties may requi re access to the relevant files, though the participant’s 
medical informat ion and the genet ic files would remain physically separate.
Data Management
Any g enetic data generated in this study will be stored at a secure system at [COMPANY_008] 
and/or designated organizations to analyse the samples.
[COMPANY_008] and its designated organizat ions may share summary results (such as genet ic 
differences fro m groups of individuals with a disease) fro m this genetic research with 
other researchers, such as hospi[INVESTIGATOR_600], academic organizat ions or health insurance 
companies. This can be done by [CONTACT_103472], where they  can 
be co mbined with the res ults of similar studi es to l earn even more about health and 
disease. The researchers can only  use thi s inform ation for heal th-related research purposes. 
Researchers may see summary results but they  will not be able to see individual 
participant data or any personal ident ifiers. 
Some or all  of the clinical datasets from the main study  may be merged wi th the genet ic 
data in a suitable secure environment separate from the clinical database.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 89of 105Appendix EMedical Device AEs, ADEs, SAEs, SADEs, [LOCATION_003]DEs and 
Medical Device Def iciencies: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting in Medical 
Device Studies
The definit ions and procedures detailed in this Appendix are in accordance wit h 
International Organizat ion for Standardizat ion [ADDRESS_401847] 2017/745 for 
clinical device research (if applicable). 
Both the Investigator and the Sponsor will co mply with all local reporting requi rements 
for medical devices.
The detecti on and docum entati on procedures described in this protocol apply  to al l 
Sponsor medical devices provided for use in the study . See Secti on 6.1.[ADDRESS_401848] of 
Sponsor medical devices.
E 1 Definition of Medical Device AE and ADE
Medical Device AE and ADE Definition
An AE is any  untoward m edical occurrence in a clinical study  parti cipant, users, or other 
persons, temporally associated with the use of study intervent ion, whether or not 
considered related to the invest igational medical devic e. An AE can therefore be any  
unfavorable and unintended sign (including an abnormal laboratory  finding), symptom, or 
disease (new or exacerbated) temporally  associated wi th the use of an invest igational 
medical device. This definit ion includes events rela ted to the invest igational medical 
device or comparator and events related to the procedures invo lved.
An adverse device effect (ADE) is defined as an AE related to the use of an invest igational 
medical device. This definit ion includes any AE result ing from insufficient or inadequate 
instructi ons for use, deplo yment, implantation, installat ion, or operation, or any  
malfunct ion of the invest igational medical device as well as any event result ing from use 
error or from intent ional misuse of the invest igational medical device.
E
2 Definition of Medical Device SAE, SADE and [LOCATION_003]DE
A Medical Device SAE is an any serious adverse event that:
a.Led to death
b.Led to serious deterioration in the healt h of the participant, that either resulted in:
A life-threatening illness or injury. The term “life -threatening” in the definit ion of 
“serious” refers to an event in which the participant was at risk of death at the time of 
the event. It does not refer to an event, which hypothetically might have caused death 
if it were more severe.
A permanent impairment of a body  structure or a body  function.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 90of 105Inpat ient or prolonged hospi[INVESTIGATOR_3094]. Planned hospi [INVESTIGATOR_95658] a pre -exist ing 
condi tion, or a procedure required by [CONTACT_760], without serious deterioration in 
healt h, is not consi dered an SAE.
Medical or surgical intervent ion to prevent life -threatening illness or injury  or 
perm anent impairment to a b ody structure or a body  function.
Chronic disease (MDR 2017/745).
c.Led to fetal distress, fetal death, or a congenital abnorma lity or bi rth defect
SADE Definition
A SADE i s defined as an adverse medical device effect that has resulted in any  of the 
consequences characterist ic of an SAE.
Any Medical Device Deficiency that might have led to an SAE if appropriate action had 
not been taken, intervent ion had not occurred, or circumstances had been less fortunate.
Unanticipated SADE ([LOCATION_003]DE) Definition
An [LOCATION_003]DE (also ident ified as UADE in [LOCATION_002] Regulat ions 21 CFR 813.3), is 
defined as a serious adverse medical device effect that by [CONTACT_5942], i ncidence, severit y, or 
outcom e has not been i dentified in the current versio n of the risk analysis report (see 
Secti on 2.2).
E 3 Definition of Medical D
evice Deficiency
Medical Device Deficiency Definition
A Medical Device Deficiency is an inadequacy o f a medical device with respect to its 
ident ity, qualit y, durabilit y, reliabilit y, safet y, or perform ance. Medi cal device deficiencies 
include malfunct ions,use errors, and informat ion supplied by [CONTACT_3455].
E 4 Recording and Follow -up of AE and/or SAE and Medical Device 
Deficiencies
AE, SAE, and Medical Device Deficiency Recording
When an AE/SAE/Medical Device Deficiency occurs, it is the responsibilit y of the 
Invest igator to review all documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, 
and diagnostics reports) related to the event.
The Investigator will then record all relevant AE/SAE/Medical Device Deficiency 
inform ation in the participant’s medical records, in accordance with the Invest igator’s 
norm al clinical pract ice and on the appropriate form.
It is notacceptable for the Invest igator to send photocopi[INVESTIGATOR_10914]’s medical 
records in lieu of co mpletion of the AE/SAE/Medical Dev ice Deficiency form.
There m ay be instances when copi[INVESTIGATOR_325355], a regulatory  authori ty, or an EC/IRB official . 
Clinical Study Protoco l -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 91of 105In thi s case, all participant identifiers, with the exce ption of  the parti cipant number, will be 
redacted on the copi[INVESTIGATOR_244877] n.
The Investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical informat ion. Whenever possible, th e diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
For m edical device deficiencies, it is very  important that the Investigator describes any 
corrective or remedial act ions taken to prevent recurrence of the deficiency.
oA remedial  action is any action other than routine maintenance or servicing o f a 
medical device where such act ion is necessary  to prevent recurrence of a Medical 
Device Deficiency. This includes any amendment to the medical device design to 
prevent recurrenc e.
Assessment of Intensity
The Investigator will make an assessment of intensit y for each AE/SAE/Medical Device 
Deficiency reported during the study  and assign it to one of the fo llowing categori es: 
Mild: An event that is easily tolerated by [CONTACT_47992], causing minimal disco mfort and 
not interfering wit h every day act ivities.
Moderate: An event that causes sufficient discomfort and interferes wit h norm al everyday 
activit ies.
Severe: An event that prevents normal every day activi ties. An AE that is asses sed as 
severe should not be confused with an SAE. “Severe” is a category  used for rating the 
intensity of an event; both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
describ ed in the definit ion of an SAE, notwhen it is rated as severe.

Assessment of Causality
The Investigator is obligated to assess the relat ionship between study  intervent ion and 
each occurrence of each AE/SAE/Medical Device Deficiency.
A “reasonable possibi lity” of a relationship conveys that there are facts, evidence, and/or 
argum ents to suggest a causal relationship, rather than a relat ionship, cannot be ruled out.
The Investigator will use clinical judgment to determine the relat ionship.
Alternat ive cause s, such as underlying disease(s), concomitant therapy , and other ri sk 
factors, as well as the temporal relationship of the event to study  intervent ion 
administration will be considered and invest igated.
The Investigator will also consult the IBin his/her assessment.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 92of 105For each AE/SAE/Medical Device Deficiency, the Invest igator must document in the 
medical notes that he/she has reviewed the AE/SAE/Medical Device Deficiency and has 
provi ded an assessment of causalit y.
There m ay be si tuations in which an SAE ha s occurred and the Investigator has minimal 
inform ation to include in the init ial report. However, it is very important that the 
Invest igator always make an assessment of causality  for every  event before the init ial 
transmissio n of the SAE data.
The Invest igator may change his/her opi[INVESTIGATOR_1649] o f causalit y in light of fo llow-up inform ation 
and send an SAE fo llow-up report wi th the updated causalit y assessment.
The causalit y assessment is one of the cri teria used when determining regulatory  reporting 
requi rements .
MDCG  2020 Guidance 
Forthepurpose ofharmonizing reports, each SAEwillbeclassified according to5different
levels ofcausalit y.The Sponsor andtheinvestigators willusethefollowingdefinit ionsto
assess the relationship of the serious adverse event totheinvestigational2device or
procedures.
1Not related: R elationship to the device or procedures can be excluded when:
theevent hasnotemporal relationship withtheuseoftheinvestigational device or the 
procedures;
                                               
2Investigational device: any device object oftheclinical investigation, including thecomparators
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 93of 105theserious event does notfollow a known response pattern tothemedical device
(iftheresponse pattern isprevi ously known) and isbiologically  implausible;
thediscont inuation ofmedicaldevice applicat ionorthereduction ofthelevelof
activat ion/exposure -when clinically feasible -and reintroducti on of itsuse(or
increase ofthelevelofactivation/exposure), do not impact on the serious event;
theevent involves a body- siteoranorgan notexpected tobeaffected by [CONTACT_10398];
theserious event canbeattributed toanother cause (eg,anunderlying orconcurrent
illness/clinical condi tion,aneffect ofanother device, drug, treatm ent or other risk 
factors);
theevent does notdepend onafalseresul tgiven by[CONTACT_325413], when applicable;
Inorder to establish the non- relatedness, notallthecriteria listed above might be metatthe
same time, depending onthetype of device/procedures and the serious event.
2 Unlikely: Therelationship withtheuseofthedevice seems notrelevant and/or the
event canbereasonably explained by[CONTACT_5748], butaddit ionalinform ation may be 
obtained.
3Possible : Therelationship with theuseoftheinvestigat ionaldevice isweak but cannot
beruledoutcompletely. Alternat ivecauses arealso possible (eg, anunderlying or
concurrent illness/ clinical condi tionor/and aneffect ofanother device, drug or
treatm ent). Cases were relatedness cannot beassessed ornoinformat ion has been 
obtained should also be classified as possible.
4Probable :The relati onship with th euseoftheinvestigational device seems relevant
and/or theevent cannot bereasonably explained by[CONTACT_5748], butaddit ional 
inform ation may be obtained.
5Causal relati onship :theserious event isassoci ated withtheinvestigational device or 
with procedures bey ond reasonable doubt when:
theevent isaknown sideeffect oftheproduct category thedevice belongs toor 
of similar devices and procedures;
theevent has atemporal relationship withinvestigat ionaldevice use/applicat ionor 
procedures;
the event involves a body -site or organ that
the invest igational device or procedures are applied to;
the invest igational device or procedures have an effect on;
theserious event followsaknown respon sepattern tothemedicaldevice (if the 
response pattern is previously known);
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 94of 105thediscontinuation ofmedical device applicat ion(orreducti on of thelevelof
activation/exposure) andreintroduction ofitsuse(orincrease ofthelevelof
activation/exposure), impact ontheserious event (when clinically feasible);
other possible causes (eg, anunderlying orconcurrent illness/ clinical condi tion
or/and aneffect ofanother device, drug ortreatment) have been adequately ruled 
out;
harm to the participant is duetoerror inuse;
theevent depends onafalseresul tgivenby[CONTACT_325414] , when applicable;
Inorder toestablish therelatedness, notallthecriteria listed abovemight bemetatthe
same time, depending onthetype of device/procedures and the serious event.
Follow -up of AE/SAE/Medical Device Deficiency
The Investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested to elucidate the 
nature and/or causalit y of the AE/SAE/Medical Device Deficiency as fully as possible. 
This m ay include addit ional laboratory  tests or investigations, histopathological 
examinat ions, or consultation with other health care profess ionals.
Suggested bullet in Variable blue text may not be required for studies where death is an 
endpo int.
New or updated informat ion will be recorded in the originally co mpleted form.
The Investigator will submit any  updated SAE data wi thin 24 hours of recei pt of  the 
inform ation.
E 5 Reporting of SAEs
SAE Reporting via Paper Data Collection Tool
Initial notificati on via telephone does not replace the need for the Invest igator to complete 
and sign the SAE paper data collection tool within the designated repo rting time frames.
Contacts for SAE reporting can be found in latest IB .
E 6 Reporting of SADEs
SADE Reporting
NOTE: There are addit ional reporting obligat ions for m edical device deficiencies that are 
potenti ally related to SAEs that m ust fulfill  the legal  responsibilit y to notify appropri ate 
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 95of 105regul atory  authori ties and other entit ies about certain safet y informat ion relating to medical 
devices being used in clinical studies.
Any Medical Device Deficiency that is associated with an SAE must be reported to the
Sponsor within 24 hours after the Investigator determines that the event meets the 
definit ion of a Medi cal Device Deficiency.
The Sponsor will review all medical device deficiencies and determine and document in 
writing whether they  coul d have l ed to an S AE. These medical device deficiencies will be 
reported to the regulatory  authori ties and IRBs/IECs as required by [CONTACT_87838].
Contacts for SAE reporting can be found in Section Appendix B.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 96of 105Appendix FChanges Related to Mitigation of Study Disruptions Due to 
Cases of Civil Crisis, Natural Disaster, or Public Health 
Crisis
Note: Changes below should be implemented only during study disrupt ions due to an y of or a 
combinat ion of civil crisis, natural disaster, or public healt h crisis (eg, during quarant ines and 
resul ting site closures, regional travel restrictions and considerat ions if site personnel or study  
participants beco me infected with severe acute respi [INVESTIGATOR_82326] e coronavirus 2 
(SARS -CoV -2) or similar pandemic infect ion) during which participants may not wish to or 
may be unable to visit the study  site for study visits. These changes should only  be 
implemented if allo wable by [CONTACT_5737]/regio nal guid elines and fo llowing agreement from  the 
Sponsor.
Reconsent of Study Participants During Study Interruptions
During study  interrupti ons, i t may not be possible for the participants to complete study  visits 
and assessments on site and alternat ive means for c arrying out the visit s and assessments may  
be necessary, eg, remote visits. Reconsent should be obtained for the alternative means of 
carrying out visits and assessments and should be obtained prior to performing the procedures 
described in Section 8.
 Local  and regi onal regulat ions and/or guidelines regarding reconsent 
of study  parti cipants shoul d be checked and followed. Reconsent may  be verbal if all owed by 
[CONTACT_325415] d regi onal gui delines (note, in the case of verbal reconsent the ICF should be signed at 
the participant’s next contact [CONTACT_72953]). Vi siting the study  sites for the sol e purpose 
of obtaining reconsent should be avo ided.
Rescreening of Participant s to Reconfirm Study Eligibility
Addit ional rescreening for screen failure due to study  disrupti on can be performed in 
previously screened part icipants. The Investigator should confirm this with the [COMPANY_008] 
Study  Physician.
In addit ion, during study  disrupt ion there may be a delay between confirming eligibilit y of a 
participant and ei ther enro llment into the study or commencing of dosing wit h study  
intervent ion.
If this delay  is outsi de the screening window specified in the SoA Table 1,  the parti cipant will 
need to be rescreened to reconfirm eligibilit y before commencing study  procedures. This will 
provi de another opportunit y to re-screen a participant in addit ion to that d etailed in 
Secti on5.5. The screening procedures detailed in Sections 1.3and  5.5must be undertaken to 
confirm eligibilit y using the same rando mizat ion number as for the participant.
Clinical Study Protocol -2.[ADDRESS_401849] On -site Visit (Where Applicable)
A qualified HCP fro m the study  site or TPV servi ce m ay visit the parti cipants’ hom e/or other 
remote locati on as per l ocal write in full  if first use SOPs, as applicable.
Supplies will be provi ded for a safe and efficient visit. The qualified HCP will be expected to 
collect informat ion per the CSP.
Telemedicine Visit to Replace On -site Visit (Where Applicable)
In thi s Appendix, the term telemedicine visit refers to remote contact [CONTACT_7089] p articipants 
using tel ecommunicat ions techno logy including telephone calls, virtual or video visits, and 
mobile health devices.
During a civil crisis, natural disaster, or public healt h crisis, on -site visi ts may  be replaced by 
a telemedicine visit if allow ed by  [CONTACT_5737]/regional guidelines. Having a telemedicine contact 
[CONTACT_325416], conco mitant m edicat ion, add other information 
including efficacy data where relevant to be collected according to study  requi rements to be 
repor ted and docum ented. 
At-home or Remote Location Study Intervention Administration Instructions
If a site visit is not possible, at -home or remote location administration of study intervention 
may be performed by a qualified HCP, provided this is acceptable within l ocal 
regul ation/guidance, or by  [CONTACT_325417]/her caregiver. The option of at -home or 
remote locati on study  intervent ion administrati on ensures participants safet y in cases of a 
pandemic where participants may be at increased risk by [CONTACT_325418]. This will also 
minimize interruption of study  interventi on administrati on during other study  disrupti ons, eg, 
site closures due to natural disaster.
At-home or Remote Location Study Intervention Administration by a Qualified HCP or 
TPV Service
A qualified HCP fro m the study  site or TPV servi ce m ay administer the study  intervent ion at 
the participant’s ho me or other remote location according to the CSP, and if allowed by [CONTACT_325419], as applicable. All necessary  supplies and instructions for administration and 
docum entati on of  study  intervent ion administration will be provided. Addit ional informat ion 
related to the visit can be obtained via a telemedicine or home visit.
Data Capture During Telemedicine or Home/Remote Visits
Data collected during telemedicine or home/remote visits will be captured by [CONTACT_73025] m the study  site or TPV servi ce in the source documents, or by  [CONTACT_73026].
Clinical Study Protocol -2.[ADDRESS_401850]
BGF budesonide, glycopyrronium, and formoterol fumarate
BID twice daily (‘ bis in die’ )
CAT COPD Assessment Test
CFC Chlorofluorocarbons
CI confidence interval
CID clinically important deterioration
CKD -EPI [INVESTIGATOR_325356] -[ADDRESS_401851] computed tomography
CTIS Clinical Trials Information System
CTR Clinical Trial Regulation
CYP3A4 cytochromeP450 3A4
DAE discontinuation due to AE
dECG digital electrocardiogram
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 99of 105Abbreviation or 
special termExplanation
DPI [INVESTIGATOR_325357]1 forced expi[INVESTIGATOR_3741] 1 second
FVC forced vital capacity
GCP Good Clinical Practice
GWP global warming potential
hCG (urine) human chorionic gonadotropin test
HFA hydrofluoroalkane
HFC (HCFC) hydrochlorofluorocarbons
HFO hydrofluoroolefin
ICD Infor med consent documents
ICF informed consent form 
ICH International Council for Harmonisation
ICS inhaled corticosteroid
IFU instruction for use
IMP Investigational medicinal product
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 100of 105Abbreviation or 
special termExplanation
IRT/RTSM Interactive Response Technology/Randomization and Trial Supply Management 
IxRS Interactive Voice/Web Response System
LABA long-acting beta 2-agonist
LAMA long-acting muscarinic antagonist
MCID minima l clinically significant difference
MDI meter ed dose inhaler
MedDRA Medical Dictionary for Regulatory Activities
NIMP Non-Investigational medicinal product
NOAEL No-Observable -Adverse -Effect -Level
NOEL No-Observable -Effect -Level
pMDI Pressurized metered- dose inhaler
PT preferred term
QTcF QT corrected for heart rate using Fridericia’s formula
RoW Rest of the World
SAE serious adverse event 
SABA short -acting beta 2-agonist
SAMA short -acting muscarinic antagonist
SARS -CoV-[ADDRESS_401852] deviation
SoA Schedule of Activities
SOC system organ class
US [LOCATION_002] of America
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 101of [ZIP_CODE] REFERENCES
Alexander et al 1995
Alexander, Dj, and Se Libretto. “An Overview of the Toxico logy of HFA -134a (1,1,1,2 -
Tetrafluoroethane).” Human &  Experimental Toxicology 14, no. 9 (September 1995): 715 –20. 
https://doi .org/10.1177/[ADDRESS_401853], Mark Holliday, Helen K. Reddel, Irene Braithwaite, Stefan Ebmeier, Robert 
J. Hancox, Tim Harrison, et al. “Controlled Trial of Budesonide –Form oterol  as Needed for 
Mild Asthma.” New England Journal  of Medicine 380, no. 21 (May  23, 2019): 2020 –30. 
https://doi .org/10.1056/NEJMoa1901963 .
Berger et al 2008
Berger, W.E., and J.A. Nadel. “Efficacy and Safety o f Form oterol  for the Treatm ent of 
Chronic Obstructive Pulmo nary Disease.” Respi[INVESTIGATOR_33593] 102, no. 2 (February  2008): 
173–88. https://doi.org/10.1016/j.rmed.2007.09.[ADDRESS_401854], A.S., McBurnie, M.A., Vollmer, W .M., Gillespie, S., Burney , P., Mannino, D.M., 
Menezes, A.M., Sullivan, S.D., Lee, T.A., Weiss, K.B., Jensen, R.L., Marks, G.B., Gulsvik, 
A., Ni zankowska -Mogilnicka, E., 2007. International variat ion in the prevalence of COPD 
(The BOLD Study ): a popul ation-based prevalence study . The Lancet 370, 741 –750. 
https://doi .org/10.1016/S0140 -6736(07)[ADDRESS_401855], P.M.A. Calver ley, et al. 
“Standards for the Diagnosis and Treatment of Patients with COPD: A Summary of the 
ATS/ERS Position Paper.” European Respi[INVESTIGATOR_21107] 23, no. 6 (June 2004): 932–46. 
https://doi .org/10.1183/09031936.04.00014304 .
Chanut et al 2013
Chanut, Franck, Carie Kimbrough, Rick Hailey , Brian Berri dge, Angela Hughes -Earle, 
Rhiannon Davies, Kimberly Ro land, et al . “Spontaneous Cardio myopathy in Young Sprague -
Dawl ey Rats: Eval uation of Bio logical  and Environmental  Variabilit y.” Toxicologic 
Pathology 41, no. 8 (December 2013): 1126 –36. https://doi.org/10.1177/0192623313478692 .
Feenstra et al 2001
Feenstra, Talit haL., Mari anne L.L. van GENUGT EN, Rudolf T. Hoogenveen, Emiel F. 
Wouters, and Maureen P.M.H. RUTTEN -van MÖLKEN. “The Impact of Aging and 
Smoking on the Future Burden of Chronic Obstructive Pulmo nary Disease: A Model  Analysis 
in the Netherlands.” American Journal of Respi[INVESTIGATOR_325358] 164, no. 4 
(August 15, 2001): 590 –96.
 https://doi .org/10.1164/aj rccm .164.4.[ADDRESS_401856], Earl  S., Janet B. Croft, David M. Mannino, Anne G. Wh eaton, Xingy ou Zhang, and 
Wayne H. Giles. “COPD Surveillance —Uni ted States, 1999 -2011.” Chest 144, no. 1 (July 
2013): 284 –305. https://doi.org/10.1378/chest.[ADDRESS_401857], Earl  S., Loui se B. Murphy , Olga Khavj ou, Wayne H. Giles, Jam es B. Hol t, and Janet B. 
Croft. “Total and State -Specific Medical and Absenteeism Costs of COPD Amo ng Adults 
Aged [ADDRESS_401858] ions Through 2020.” Chest 147, no. 1 
(January 2015): 31 –45.
 https://doi .org/10.1378/chest.14 -0972.
Halpin et al 2017
Halpin, David M.G., Marc Decramer, Bartolo me R. Celli, Achim Mueller, Norbert Metzdorf, 
and Donald P. Tashkin . “Effect of a Single Exacerbat ion on Decline in Lung Funct ion in 
COPD.” Respi[INVESTIGATOR_33593] 128 (July 2017): 85
–91. 
https://doi .org/10.1016/j .rmed.2017.04.013 .
Hatcher et al 2003
Hatcher RA, Trus sell J, Nelson AL, Cates W Jr, Stewart F, Kowal D, eds. Contraceptive 
techno logy. 19th edi tion. [LOCATION_001]: Ardent Media, 2007(a): 24. Table 3-2. Jackson, H., 2003. 
Detecting chronic obstructive pulmo nary disease using peak flow rate: cross sectional survey . 
BMJ 327, 653–654. https://doi.org/10.1136/bmj.327.7416.653
Jackson 2003
Jackson, H. “Detecting Chronic Obstructive Pulmo nary Disease Using Peak Flow Rate: Cross 
Secti onal Survey.” BMJ 327, no. 7416 ( September 20, 2003): 653 –54. 
https://doi .org/10.1136/bmj.327.7416.[ADDRESS_401859]. European Respi[INVESTIGATOR_325359]  34, 648 –654. https://doi.org/10.1183/09031936.[ADDRESS_401860] on pulmo nary drug devel opment. 
Respir. Care 2005; 50(9):1201- 1208.
Levey 2009
Levey , A.S., Stevens, L.A., Schmid, C.H., Zhang, Y. (Lucy ), Castro, A.F., Feldman, H.I., 
Kusek, J.W., Eggers, P., Van Lente, F., Greene, T., Coresh, J., for the CKD -EPI (Chroni c 
Kidney Disease Epi [INVESTIGATOR_325328]), 2009. A New Equation to Estimate Glomerular 
Filtration Rate. Annals o f Internal Medicine 150, 604. 
https://doi .org/10.7326/0003 -
4819-150-9- 200905050 -[ZIP_CODE]
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 103of 105Levy 2015
Levy , Mark L. “The Nat ional Review of Asthma Deaths: What Did We Learn and What 
Needs to Change?” Breathe 11, no. 1 (March 2015): 14 –24. 
https://doi .org/10.1183/20734735.008914 .
Louis et al 2022
Louis, Renaud, Imran Satia, Inigo Ojanguren, Florence Schleich, Matte o Bonini, Tho my 
Tonia, David Rigau, et al. “European Respi[INVESTIGATOR_325360].” European Respi[INVESTIGATOR_21107] , February  15, 2022, 2101585. 
https://doi .org/10.1183/13993003.[ADDRESS_401861]. “Cardiac Arrhy thmias and Bl ood Levels 
Associ ated wi th Inhalat ion of Halo n 1301.” American Industrial Hygiene Association Journal
40, no. 7 (July 1979): 653–58. https://doi.org/10.1080/[ADDRESS_401862], o n iso lated human bronchi. European Respi[INVESTIGATOR_325359]  29, 575 –581.
 https://doi.org/10.1183/09031936.00032806
O'By[CONTACT_129120] 2017
O’By[CONTACT_7943], Paul M., Christine Jenkins, and Eric D. Bateman. “The Parado xes of Asthma 
Management: Time for a New Approach?” European Respi[INVESTIGATOR_21107] 50, no. 3 
(September 2017): 1701103. https://doi.org/10.1183/13993003.[ADDRESS_401863], John N. “The Climate Is Changing for Metered- Dose Inhalers and Act ion Is 
Needed.” Drug Design, Development and Therapy Volume 14 (July  2020): 3043 –55. 
https://doi .org/10.2147/DDDT.S262141 .
Quanjer [ADDRESS_401864] ion Init iative, 
2012. Mult i-ethnic reference values for spi[INVESTIGATOR_14436] 3–95- yr age range: the global lung 
funct ion 2012 equations. European Respi[INVESTIGATOR_21107] 40, 1324 –1343. 
https://doi .org/10.1183/09031936.[ADDRESS_401865] D ekhuijzen. “The Evolut ion of Pressurized Metered -Dose 
Inhalers fro m Early to Modern Devices.” Journal of Aerosol Medicine and Pulmonary Drug 
Delivery 29, no. 4 (August 2016): 311–27. https://doi.org/10 .1089/jamp.2015.1232 .
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 104of 105Rusch 2018
Rusch, George M. “The Development of Environmentally Acceptable Fluorocarbons.” 
Critical Reviews in Toxicology 48, no. 8 (September 14, 2018): 615 –65. 
https://do i.org/10.1080/10408444.2018.1504276 .
Sastre et al 2016
Sastre, Joaquin, Leonardo M. Fabbri, David Price, Hans Ulrich Wahn , Jean Bousquet, James 
E. Fish, Kevin Murphy, and Malco lm R. Sears. “Insights, Attitudes, and Perceptions about 
Asthma and Its Treatment: A Mult inational Survey of Patients fro m Europe and Canada.” 
World Allergy Organization Journal 9 (2016): 13. https://doi .org/10.1186/s40413- 016-0105-
4.
Schreiber et al 2020
Schreiber, Jens, Tina Sonnenburg, and Eva Luecke. “Inhaler Devices in Asthma and COPD 
Patients –a Prospective Cross -Secti onal Study  on Inhaler Preferences and Error Rates.” BMC 
Pulmonary Medicine 20, no. 1 (December 2020). https://doi.org/10.1186/s12890 -020-
[ZIP_CODE]-
z.
Schuster et al 2009
Schuster, Paul, Rüdiger Bertermann, George M. Rusch, and Wo lfgang Dekant. 
“Biotransform ation of Trans -1,1,1,3 -Tetrafluoropropene (HFO -1234ze).” Toxicology and 
Applied Pharmacology 239, no. 3 (September 15, 2009): 215–23. 
https://doi .org/10.1016/j .taap.2009.06.018 .
Sellers 2017
Sellers, William F. S. “Asthma Pressurised Metered- Dose Inhaler Performance: Propellant 
Effect Studies in Delivery  Systems.” Allergy, Asthma &  Clinical Immunology 13, no. 1 
(December 2017). https://doi.org/10.1186/s13223 -017-
0202-0.
Suissa et al 2012
Suissa, Samy , Sophie Dell’Aniello, and Pi[INVESTIGATOR_325361]. “Long- Term  Natural  History  of Chronic 
Obstructive Pulmo nary Disease: Severe Exacerbat ions and Mortali ty.” Thorax 67, no. 11 
(November 2012): 957–63. https://doi.org/10.1136/thoraxjnl -2011-
201518.
Ulm 1990
Ulm, K. “SIMPLE METHOD TO CALCULATE THE CONFIDENCE INTERVAL OF A 
STANDARDIZED MORT ALITY RATIO (SMR).” American Journal of Epi[INVESTIGATOR_623] 131, 
no. 2 (February  1990): 373 –75. https://doi.org/10.1093/oxfordjournals.aje.a115507 .
Usmani et al 2019
Usmani, Omar S, Jane Scullio n,and Duncan Keeley. “Our Planet or Our Patients —Is the Sky  
the Limit for Inhaler Cho ice?” The Lancet Respi[INVESTIGATOR_33593] 7, no. 1 (January  2019): 11 –
13.
 https://doi.org/10.1016/S2213- 2600(18)30 497
-1.
Clinical Study Protocol -2.0 [COMPANY_008]
PT010 - D5985C00003
CONFIDENTIAL AND PROPRIETARY 105of 105Wheaton et al 2019
Wheaton AG, Liu Y, Croft JB, et al. Chronic Obstructive Pulmo nary Disease and Smoking 
Status —[LOCATION_002], 2017. MMWR Morb Mortal Wkly Rep 2019;68:533 –538. DOI: 
http://dx.doi.org/10.[ZIP_CODE]/mmwr.mm6824a1
Wilkinson et al 2019
Wilk inson, Alexander J K, Rory  Braggins, Ingeborg Steinbach, and James Smith. “Costs of 
Switching to Low Gl obal Warming Potenti al Inhalers. An Economic and Carbon Footprint 
Analysis of NHS Prescript ion Data in England.” BMJ Open 9, no. 10 (October 2019): 
e0287 63. https://doi.org/10.1136/bmjopen -2018- 028763 .
CPMP/ICH/375/95
ICH Topi c E 1. Popul ation Exposure: The Extent of Populat ion. 
Exposure to Assess Clinical 
Safety. June 1995
Global strategy  for the di agnosis, management, and prevention of COPD. Global Init iative for 
Chronic Obstructive Lung Disease (GOLD) 2021. https://goldcopd.org/
Workplace Environmental Exposure Level (WEEL). 2012. Workplace Environmental 
Exposure Level Gui de: Difluoroethane. Fairfax (VA): American Industrial Hygiene 
Associ ation
https://www.cdc.gov/dotw/copd/index.ht ml
https://www.who.int/news -room /fact-sheets/detail/the -top-10-causes -of-death 
https://www.thoracic.org/professio nals/clinical -resources/asthm a-cente r/guidelines.php
https://www.m ed.unc.edu/medicine/wp -content/uploads/sites/945/2018/12/inhaler- pi[INVESTIGATOR_1103] -
guide.pdf
http://www.honeywell -solsticelba.co m/wp -content/upl oads/2011/09/l ow-GWP -blowing -
agent -Honey well-nextgenerat ion-paper -2011.pdf
SIGNATURE [CONTACT_73032] a representation of an electronic record that was signed
electronically and this page is the manifestation of the electronic signature
[CONTACT_24558]: d5985c00003-csp-v2
Document Title: D5985C00003 Clinical Study Protocol version 2
Document ID: Doc ID-004816084
Version Label: 2.[ADDRESS_401866] APPROVED
Server Date
(dd-MMM-yyyy HH:mm ‘UTC’Z)Signed by [CONTACT_24557]
14-Dec-2023 15:28 UTC Content Approval
14-Dec-2023 15:56 UTC Content Approval
14-Dec-2023 19:21 UTC Content Approval
15-Dec-2023 13:28 UTC Content Approval
Notes: (1) Document details as stored in ANGEL, an [COMPANY_008] document management system.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]